Avian Metapneumovirus Reverse Genetics Developments and their Effect on the Performance of Recombinant Live Vaccines by Laconi, Andrea
Alma Mater Studiorum – Università di Bologna 
 
 
DOTTORATO DI RICERCA IN 
 
Scienze Veterinarie 
 
Ciclo XXVIII 
 
Settore Concorsuale di afferenza: 07/H3 
 
Settore Scientifico disciplinare: VET05 
 
 
AVIAN METAPNEUMOVIRUS REVERSE GENETICS DEVELOPMENTS 
AND THEIR EFFECT ON THE PERFORMANCE OF RECOMBINANT 
LIVE VACCINES 
 
 
 
 
Presentata da: Andrea Laconi 
 
 
 
 
Coordinatore Dottorato     Relatore 
 
 
Prof. Carlo Tamanini      Prof.ssa Elena Catelli 
      
         Correlatore 
 
         Dr. Clive J. Naylor 
 
 
 
  
Esame finale anno 2016
i 
 
TABLE OF CONTENT 
            Page 
1 INTRODUCTION         1 
2. LITERATURE REVIEW        3 
2.1 AVIAN METAPNEUMOVIRUS LITERATURE REVIEW 3 
2.1.1 Aetiology        3 
2.1.1.1 Morphology      3 
2.1.1.2 Genome       4 
2.1.1.3 Proteins       5 
2.1.1.4 Virus attachment, transcription and replication 5 
2.1.1.5 Chemical and physical properties   7 
2.1.1.6 Strain classification     7 
2.1.1.7 Nucleotide and amino acid identity   7 
2.1.2 Epidemiology       8 
2.1.2.1 Host        8 
2.1.2.2 Distribution      9 
2.1.2.3 Transmission      10 
2.1.3 Pathogenesis        10 
2.1.4 Symptomatology       12 
2.1.5 Post-mortem        13 
2.1.5.1 Gross lesions      13 
2.1.5.2 Microscopic lesions     14 
2.1.6 Immune response       15 
2.1.7 Diagnosis        16 
2.1.7.1 Virus isolation      16 
2.1.7.2 Viral detection      17 
ii 
 
2.1.8 Disease control       18 
2.2 REVERSE GENETICS LITERATURE REVIEW   20 
3. GENERAL MATERIALS AND METHODS     22 
3.1 Nucleic acid extraction       22 
3.2 Reverse transcription       22 
3.3 Polymerase chain reaction       23 
3.4 Agarose gel electrophoresis      25 
3.5 Sequencing         26 
3.6 Ligation          26 
3.7 Site directed mutagenesis        27 
3.8 Transformation and liquid culture      28 
3.9 Restriction enzyme digestion      28 
4. A COMPARISON OF AMPV SUBTYPE A AND B FULL 
 GENOMES, GENE TRANSCRIPTS AND PROTEINS LED  
TO REVERSE GENETICS SYSTEMS RESCUING BOTH SUBTYPES 30 
4.1 Introduction         30 
4.2 Materials and methods       33 
4.2.1 Viruses        33 
4.2.2 Determination of leader and trailer sequences  34 
4.2.3 Determination of 3’ termini of subtype A and B AMPV  
 mRNAs        34 
4.2.4 Determination of viral gene sequences and their  
 comparison        35 
4.2.5 Construction of subtype B reverse genetics system  35 
4.2.5.1 Preparation of pSMART plasmid vector  35 
4.2.5.2 Subtype B genome copy construction  36 
iii 
 
4.2.5.3 Preparation of B type support plasmids  37 
4.2.6 Recovery of viruses      41 
4.3 Results          41 
4.3.1 Determination and comparison of leaders and trailers 
 sequences        41 
4.3.2 Determination and comparison of gene start and stop 
 sequences        42 
4.3.3 Comparison of viral protein sequences   46 
4.3.4 Construction of subtype B reverse genetics    
 system           47 
4.3.4.1 pSMART plasmid vector preparation  47 
4.3.4.2 AMPV-B full genome copy plasmids  47 
4.3.4.3 Support genes plasmids    48 
4.3.5 Recovery of virus from AMPV full length copies  48 
4.4 Discussion         49 
5. MAKING AND TESTING SUBTYPE B AVIAN  
METAPNEUMOVIRUS IBV RECOMBINANTS    53 
51. Introduction         53 
5.2 Materials and methods       55 
5.2.1 Addition of the cloning cassette     55 
5.2.2 IBV S1 and N genes amplification and insertion  55 
5.2.3 Recovery of recombinant viruses    57 
5.2.4 S1 and N genes transcription     58 
5.2.5 In vivo trial        58 
5.2.6 Serology        58 
5.2.7 Recombinants replication in vivo    59 
5.2.8 Determination of tracheal cilia activity   59 
iv 
 
5.3 Results          59 
5.3.1 IBV recombinants AMVP-B construction   59 
5.3.2 Recovery of the recombinant viruses    60 
5.3.3 Serology        60 
5.3.4 Recombinants replication in vivo    61 
5.3.5 Tracheal motility following challenge    61 
5.4 Discussion         62 
6. IMPROVING THE REPLICATION IN VIVO OF SUBTYPE B  
AVIAN METAPNEUMOVIRUS IBV RECOMBINANTS   64 
6.1 Introduction         64 
6.2 Materials and methods       65 
6.2.1 Subtype B vaccines comparison    65 
6.2.2 Chimera AMPV-B construction    66 
6.2.3 IBV S1 and N genes amplification and insertion  66 
6.2.4 Interleukin-18 (IL-18) gene amplification and insertion 67 
6.2.5 Recovery of recombinant viruses    68 
6.2.6 Exogenous genes transcription     71 
6.2.7 Exogenous proteins expression     71 
6.2.8 Sequences comparison of two cBN G-L plasmids  71 
6.2.9 In vivo trial        72 
6.2.10 Recombinants replication in vivo    72 
6.2.11 Determination of tracheal cilia activity   72 
6.3 Results          73 
6.3.1 Subtype B vaccines comparison    73 
6.3.2 Chimera AMPV-B construction    85 
6.3.3 Exogenous genes addition     85 
6.3.4 Recovery of recombinant viruses    87 
v 
 
6.3.5 Sequences comparison of two cBN G-L plasmids  87 
6.3.6 Exogenous genes transcription and expression  88 
6.3.7 Recombinants replication in vivo    88 
6.3.8 Tracheal motility following challenge    89 
6.4 Discussion         89 
7. INVESTIGATING THE ABILITY OF SUBTYPE B AVIAN 
METAPNEUMOVIRUS TO ACCEPT EXOGENOUS GENES AT  
MULTIPLE INTERGENIC POSITIONS      94  
7.1 Introducion         94 
7.2 Materials and methods       96 
7.2.1 Plasmids preparation      96 
7.2.1.1 N gene cloning in the M-F intergenic region 
 of the chimera vector (cvB).     96 
7.2.1.2 N gene cloning in the M-F intergenic region of 
plasmids containing the S1 and IL-18 genes in the G-L 
intergenic region (cBS1+IL-18 G-L)    97 
7.2.1.3 M gene cloning in the M-F integenic region 
 of plasmids containing the S1 and IL-18 (cBS1+IL-18 G-L) 
 genes in the G-L intergenic region    97 
7.2.1.4 M gene cloning in the G-L intergenic region of 
plasmids containing the N gene in the M-F intergenic 
 region        98  
7.2.1.5 S1 gene cloning in the G-L intergenic region of 
plasmids containing the N gene in the M-F intergenic 
 region        98 
7.2.2 Recovery of recombinant viruses    98 
7.3 Results          100 
vi 
 
7.3.1 Genes addition       100 
7.3.2 Recovery of recombinant viruses    101 
7.3.2.1 cBN M-F rescue attempts     101 
7.3.2.2 cBN M-F S1+IL-18 G-L and cBM M-F S1+IL-18 G-L  
rescue attempts       101 
7.3.2.3 cBN M-F S1 G-L rescue attempts    101 
7.3.2.4 cBN M-F N G-L rescue attempts    102 
7.4 Discussion         102 
8. CONCLUSION          105 
9. REFERENCES          109 
 
 
 
 
 
 
 
 
 
1 
 
1. INTRODUCTION 
Avian metapneumovirus (AMPV) is an enveloped negative sense single stranded 
RNA virus, which is a major endemic respiratory pathogen of global domestic 
poultry. The virus causes acute respiratory tract infection in turkeys characterized 
by sneezing, tracheal râles, swollen sinuses and nasal discharge (Naylor and Jones., 
1993). Infection of chickens results in a drop in egg production from laying birds 
and can be associated with swollen head syndrome (SHS) (Cook, 2000). Four 
subtypes of AMPV have been recognized worldwide: A, B, C and D. Subtypes A 
and B have now been reported in most countries worldwide, whilst subtype C has 
only been reported in the USA (Seal, 1998), France (Toquin et al., 2006), China 
(Sun et al., 2014; Wei et al., 2013) and in one case in Korea (Lee et al., 2007). 
Subtype D has only been reported in France (Bayon-Auboyer et al., 2000). Reverse 
genetic (RG) techniques have been applied to subtype A (Naylor et al., 2004) and 
C (Govindarajan et al., 2005); several reports have investigated the effects of single 
and multiple genomic mutations and gene deletions (Ling et al., 2008; Naylor et al., 
2004) or insertions (Falchieri et al., 2013) on viral biology. A subtype B RG system 
has not been yet developed. This subtype is distributed worldwide and growing field 
evidence suggests it to be more able to infect commercial chickens compared to 
subtype A. For these reasons it would be convenient to have a RG system available 
also for B viruses. The aims of this study was to developed a RG system for AMPV 
subtype B and gain a better understanding of the viral capacity to accept and express 
heterologous extra sequences in order to developed effective AMPV recombinant 
vaccines.  
In chapter 4 a comparison of subtype A and B viruses was performed to assess 
whether subtype A RG components could be partially or fully substituted. AMPV 
subtype A and B gene end sequences, as well as several leader and trailer sequences 
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were obtained. After comparing these data, reported gene start sequences and 
protein sequences, it was concluded that subtype B genome copies would be likely 
to be rescued by a subtype A support system. Individual subtype A components 
were substituted with subtype B components. A fully subtype B RG system was 
obtained using an advance cloning plasmid, and proved that all subtype specific 
components could be freely exchanged between A and B systems.  
In chapter 5 was assessed the ability of subtype B to accept and express foreign 
genes, specifically spike (S1) and nucleocapsid (N) genes of infectious bronchitis 
virus (IBV). Recombinant viruses had been recovered by RG and proved to be able 
to express the inserted genes efficiently and to be stable during passage in vitro. 
Subsequently AMPV-B/IBV recombinants were tested as candidate vaccines by 
eye-drop inoculation of one-day-old chickens and challenged with IBV.  
Chapter 6 investigates how to increase the protection induce by subtypes the 
recombinants. In a first study the genes involved in the replication process were 
modified to increase the replication in vivo. At the same time, the Interleukin 18 
(IL-18) was added in the recombinants: IL-18 is known to play an important role in 
the inflammatory reaction in chickens. Viruses have been recovered and challenged 
in vivo against IBV.  
In chapter 7 is described the attempts to develop viruses able to express multiple 
IBV proteins. The matrix (M) sequence of IBV was added in construct containing 
the S1 or the N genes. At the same time the exogenous genes were inserted in 
different positions along the AMPV genome sequence. Several constructs 
containing up to 3 exogenous genes were obtained. 
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2. LITERATURE REVIEW 
 
2.1 AVIAN METAPNEUMOVIRUS LITERATURE REVIEW 
 
2.1.1 AETIOLOGY 
Avian metapneumovirus (AMPV) belongs to the Metapneumovirus genus; 
Metapneumoviruses are part of the subfamily Pneumovirinae within the 
Paramyxoviridae family, including single stranded, negative sense RNA, and 
enveloped viruses (Pringle, 1998; Van den Hoogen et al., 2001; Van Regenmortle 
et al., 2000). Human metapneumovirus (HMPV) it’s the only other virus belonging 
to this genus. 
 
2.1.1.1 Morphology 
The virus can be seen by electronic microscopy; the viral particles appear 
pleomorphic, with shape ranging from spherical to filamentous. The viral particles 
size is also variable, ranging from 40 to 500nm. The nucleocapsid is characterized 
by a helical shape and on the envelope surface projections of about 13 – 14 nm are 
clearly distinguishable (Baxter-Jones et al, 1987; Buys et al., 1989; Collins et al., 
1986; Cook et al., 2002; Giraud et al., 1986; Gough et al., 1989; McDougall et al., 
1986; Wyeth et al., 1986). 
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Figura 2.1 AMPV observed using electronic microscopy 
 
2.1.1.2 Genome 
AMPV is characterised by a negative sense single stranded RNA genome of about 
13000 - 14000 nucleotides (Randhawa et al., 1997). The genome encodes for 8 
genes: these 8 genes are translated in at least 9 proteins. The order of the gene from 
the 3’ end to the 5’ end is the following: N, P, M, F, M2 (including two overlapping 
open reading frames), SH, G and L (Easton et al., 2004; Ling et al., 1997). Every 
gene is flanked by a transcriptional start sequence and a transcriptional stop 
sequence, and between each transcriptional unit there are intergenic untranslated 
regions. Both the 3’ end (leader) and the 5’ end (trailer) of the genome show a 
complementary untranslated sequence of about 40 bases: these sequences contain 
promoters and are involved in the processes of transcription, replication and 
packaging (Ling et al., 2008; Wheelan et al., 2004).  
 
 
Figure 2.2 AMPV genome 
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2.1.1.3 Proteins 
The 8 genes encode for 9 proteins. The Nucleocapside protein (N) forms the 
nucleocapside and it joins to the genome, being responsible for the helicoidal 
structure of the RNA (Easton et al., 2004). The phosphoprotein (P), together with 
the RNA dependent Polymerase (L) protein, forms the ribonuclear complex (RNP). 
Those two protein are involved in the processes of genome replication and genes 
transcription (Broor and Baraj, 2007). The Matrix (M) protein is situated in the inner 
envelope surface, anchoring the nucleocapside to the lipidic membrane. In contrast 
with the other genes, the Matrix 2 gene (M2) encodes for two different proteins: 
M2-1 protein, which seems to behave as a transcription elongation factor and M2-2 
protein which is thought to act in the transition from the replicative phase to the 
assembly phase of the virion before the release of the latest from the host cell 
surface. The remaining three proteins are the glycoproteins of the envelope: the 
small hydrophobic protein (SH) is an integral membrane polypeptide; however its 
function is poorly understood. The Fusion (F) and the attachment (G) proteins, 
located on the external part of the envelope, are recognised as the major antigenic 
determinants of the virus (Broor and Baraj, 2007).  
 
2.1.1.4 Virus attachment, transcription and replication 
The protein involved in the attachment of the virus to the host cell receptors is the 
G protein. Once the virus is attached to the host cell surface, the F protein enables 
the fusion of the envelope with the cell membrane, leading to the release of the 
nucleocapside into the cytoplasm (Easton et al., 2004). AMPV, as all negative 
stranded RNA virus, needs a ribonuclear complex (RNP) both for the transcription 
and the replication: thus, to initiate an infectious cycle, the viral genome is 
incorporated in the nucleoprotein (N) and linked with the RNA dependent 
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Polymerase (L) and the phosphoprotein (P), that acts as cofactor. The polymerase 
enter the genome at the 3’ end; the synthesis of the positive sense mRNA starts at 
the first transcription start sequence and stop at the first transcription stop sequence. 
At this stage the polymerase molecules can either move along the genome, 
beginning to transcribe a new gene binding at the following transcription start, or 
dissociate from the RNA and rebind to the 3’ end, beginning the synthesis of the 
first mRNA. This mechanism applies to every transcription stop along the whole 
genome, therefore at every junction the polymerase can dissociate from the genome. 
The obvious consequence of the process is a gradually decrease in the mRNA 
production, moving from the 3’ end to the 5’ end (Dimmock et al., 2007). To a 
major mRNA synthesis correspond a major protein production.  
To generate the positive sense copy of the genome the RNA dependent Polymerase 
must ignore the transcription start and stop flanking each gene, but the mechanism 
behind this behaviour of the L protein is still not clear. One hypothesis, suggested 
by studies on human respiratory syncytial virus (HRSV), is that the concentration 
of the N protein in the cytoplasm may play a role in the regulation of the process 
(Fearns et al., 1997). The positive sense copy of the genome is then used as template 
for a new negative sense RNA full genome. The new synthetized negative sense 
RNA genome forms a new RNP together with N, P and L proteins. The assembly 
process is led by the M proteins: this protein interacts with the RNP and the surface 
proteins, SH, G and F, which after synthesis have been inserted into the cell 
membrane; these last interactions, in particular, results in virions budding from the 
cell surface. (Easton et al., 2004). 
 
 
 
7 
 
2.1.1.5 Chemical and Physical properties 
AMPV is stable in a pH range between 3 and 9, it’s inactivated at 56°C in 30 minutes 
and it’s sensible to lipoid solvent as ether and clorophorm (Collins et al., 1986). 
Aldehydes, alcohols, phenols and organic acids inactivate the virus (Hafez and 
Arns, 1991). AMPV is resistant to drying for 7 days but could survive for several 
days in turkey litter at different temperatures (Velayudhan et al., 2003). Autoclave, 
microwaving and high-pressure treatment are able to inactivate the virus. 
 
2.1.1.6 Strain classification 
Four subtypes of AMPV have been recognized worldwide: A, B, C and D. Most of 
the detection in Western Europe have involved subtypes A and B, with the exception 
of a French strains, isolated in 1985, resulted in the identification of subtype D 
(Bayon-Auboyer et al., 2000; Collins et al., 1993). In North America in 1997 was 
isolated a strain identified as subtype C (Seal, 2000). The first differentiations were 
performed using serological test (ELISA, seroneutralization, immunofluorescence), 
but now a day the sequencing of the F and the G genes is used (Collins et al., 1993; 
Naylor et al., 1998; Seal et al., 2000).  
 
2.1.1.7 Nucleotide and amino acid identity 
Subtypes A and B show a nucleotide identity about 56-61% whereas within 
subtypes it is 97-99% (Lwamba et al., 2005). Subtype C isolates have been reported 
to share 89-94% nucleotide identity, compared with 60-65% with subtypes A and 
B (Shin et al., 2002). A recently full genome sequence of the subtype D isolate, 
reveal that it is more related to subtype A and B rather than C (Brown et al., 2014). 
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The predicted amino acid (aa) sequence confirms that subtypes A, B and D are 
closer than subtype C. N, P, M and F are the most conserved sequences, with an aa 
identity up to 90% between subtypes A and B and about 50-70% between those two 
subtypes and subtype C (Jacobs et al., 2005;Li et al., 1996; Naylor et al., 1998; 
Randhawa et al., 1996; Seal, 1998; Seal et al., 2000; Shin et al., 2002).  The M2:1 
protein is very conserved in all the subtypes, with identities ranging from the 64% 
to the 89%, while the M2:2 is more variable: A and B type share the 71% of their 
aa sequence, while the percentage of identity decrease to the 20% when compare to 
the C type (Dar et al., 2003; Jacob et al., 2005). High variability has been observed 
in the SH and the G proteins where the identity is of 47% and 38% respectively 
between subtypes A and B and only 18% and 15% for subtype C in comparison 
with the other two subtypes (Govindarjan et al, 2004; Lwamba et al., 2005). The L 
gene share a 85% of identity between subtype A and B, while it decrease to 62.5% 
when compare with the C type L aa sequence (Lwamba et al., 2005; Sugiyama et 
al., 2010) 
 
2.1.2 EPIDEMIOLOGY 
2.1.2.1 Host 
The natural hosts of AMPV are turkeys and chickens, with the first specie 
considered the most susceptible, as well as the first specie in which was observed 
the disease, firstly called Turkeys Rhinotracheitis (TRT) (Buys and Du Preez, 1980; 
Gough and Jones, 2008). Guinea fowls and pheasants are susceptible to the 
infection, as suggested by field evidences and experimental infection studies 
(Catelli et al., 2001; Gough el at, 1988; Horner et al., 2003; Laconi et al., 2014). 
Pigeons, ducks and geese seem resistant to the infection due to AMPV subtypes A 
and B (Gough et al., 1988); however some field studies carried on in North America 
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showed a low level of sensitivity to subtype C (Shin et al., 2000a; Turpin et al., 
2008), as confirmed by experimental infection studies (Toquin et al., 2006a; Toquin 
et al., 2006b). Farmed ostriches in Zimbabwe were found serologically positive to 
AMPV, as well as some birds imported in Italy from Africa (Cadman et al., 1994; 
Capua, 1998). In general, wild species have been proven to be sensitive to AMPV 
subtype C, while the role of the other subtypes in the wild species is still not fully 
understood (Bennet el al., 2002; Bennet et al., 2004; Heffels-Redman et al., 1998; 
Turpin et al., 2008).  
 
2.1.2.2 Distribution 
AMPV has been detected worldwide, with the exception of the Australian continent 
(Bell et al., 1990). The disease has been seen for the first time in turkey farms in 
South Africa in the late ‘70’s (Buys and Du Preez, 1980). Since then the virus spread 
rapidly in Europe and the first detection has been done in France in early ‘80s 
(Andral et al., 1985). In the following years the virus has been detected in others 
European countries: Germany (Hafez and Woernle, 1989), Spain and Italy (Fabris 
and D’aprile, 1990), Hungary (Lantos, 1990), Croatia (Bidin et al., 1990), Austria 
(Polland et al., 1992), Poland (Minta et al., 1995), Sweden (Engstroom et al., 2000) 
and Russia (Botchkov et al., 2002). In the same period the infection has been 
detected also in non-European countries such as Israel (Weisman et al., 1988), 
Yemen (Sarakbi, 1989), Japan (Uramoto et al., 1990), Mexico (Decanini et al., 
1991), Morocco (Houadfi et al., 1991), Brasil (Arns and Hafez, 1992), Zimbabwe 
(Cadman et al., 1994), Taiwan (Lu et al., 1994), Caribe (Jones, 1996), Chile (Toro 
et al., 1998), Jordan (Gharaibeh and Algharaibeh, 2007), China and Nigeria 
(Owoade et al., 2008). The first detection of AMPV in North American has been 
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reported only in 1996 in Colorado (Senne et al., 1997), followed by an outbreak in 
Minesota in 1997. 
The geographical distribution of the AMPV subtypes is interesting: meanwhile 
subtypes A and B showed a worldwide distribution, with the exception of Oceania 
and North America, the subtype C seems to be present only in the latest, even if 
more recently this subtype has been isolated in France and North Korea (Toquin et 
al., 2006; Lee et al., 2007). The subtype D has been detected only during an outbreak 
in France in 1985 and to date no others detection of this subtype has been reported 
(Bayon Auboyer et al., 2000). 
 
2.1.2.3 Transmission 
AMPV is a virus not able to resist out of the host. This evidence and the replication 
limited to the respiratory tract suggest that the direct contact transmission, both 
directly with infected animals or their respiratory discharges, is the most probable 
way of infection. It’s highly unlikely the existence of vectors and the virus is not 
able to give latency in the host. Nevertheless, infected water, the movement of 
infected birds, equipment, personnel and feed trucks can play a role in the spread of 
the virus (Stuart, 1989). Some evidences suggest that a role in the transmission may 
be play by wild birds, but the transmission between wild and domestic birds has not 
been proven yet (Gough and Jones, 2008). 
 
2.1.3 PATHOGENESIS 
AMPV infected the upper respiratory tract: the nasal cavities, concha, infraorbital 
sinus and trachea are considerate not only the first replicative site of the virus, but 
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in general the main target tissues for viral replication. Less frequently the virus 
could be detected in the lungs and in the air sacs. In the tissues of the upper 
respiratory tract the virus can be detected by immunofluorescence up to 9 days post 
infection (d.p.i.) and can be isolated up to 14 d.p.i. in both turkeys and chickens, 
confirming that the tissues distribution and the replication rate are very similar in 
these two species (Catelli et al., 1998; Cook et al., 1991; Jones et al., 1988). Using 
molecular biology techniques, Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR), the viral RNA has been detected in the trachea up to 19 d.p.i. (Li et al., 
1993). The virus can reach the reproductive apparel and replicates in the oviduct 
causing a reduction of the eggs production (Cook et al., 2000; Hess et al., 2004; 
Jones et al., 1988; Sugiyama et al., 2006; Villareal et al., 2007). Even if the 
mechanism of the spread to other organs is not clear, AMPV has also been 
occasionally detected in the Harderian gland, kidneys (Khehra and Jones, 1999), 
spleen, cecal tonsil and bursa of Fabricious (Aung et al., 2008). A transient viremia 
could be an explanation of the spread of the virus, but AMPV is rarely detected in 
the blood, thus this phenomenon needs to be investigating further (Shin et al., 
2000b). The penetration to the lower tract of the respiratory apparel can be 
facilitated by bacterial co-infection. Several bacterial have proven to be involved in 
this process: Escherichia coli (Al-Ankari et al., 2001; Turpin et al., 2002; Van de 
Zande et al., 2001), Bordetella avium (Cook et al., 1991; Jirjis et al., 2004), 
Mycoplasma gallisepticum (Naylor et al., 1992) and Mycoplasma imitans 
(Ganapathy et al., 1998), Riemerella anatipestifer (Rubbenstroth et al., 2009), 
Chlamydophila psittaci (Van Loock et al., 2005) and Ornithobacterium 
rhinotracheale (Marien et al., 2005). The co-infection with bacterial can cause an 
exacerbation of the disease and can enhance the viral distribution in the host. Viral 
co-infections seem to have the opposite effect: Infectious bronchitis virus (IBV) 
inhibits AMPV replication in the upper respiratory tract. Considering the different 
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subtypes, no clear differences have been found in the pathogenesis (Aung et al., 
2008; Shin et al., 2000b; Van de Zande et al., 1999). 
 
2.1.4 SYMPTOMATOLOGY  
The specie more severely affected is Turkeys, while in chickens the infection is 
often asymptomatic or with mild symptom. Affected turkeys showed the typical 
respiratory disease symptoms: coughing, sneezing, nasal discharge, swollen 
infraorbital sinus, conjunctivitis and submandibular oedema followed by depression 
and decrease in feed intake (Buys et al., 1989; Jones et al., 1986; McDougall and 
Cook, 1986). The morbidity is generally very high; it can reach 100%, while the 
mortality is highly variable, ranging from 0% to 50%, and age dependent (Hafez; 
1993; Pattison, 1998; Stuart, 1989). The severity of the disease depends on 
management factors, such as birds’ density, ventilation, temperature, hygienic 
conditions, and on secondary bacterial infections (Gough and Jones 2008; Hafez, 
1993). Without any complications the recovery from the disease is quick and the 
symptoms generally disappear in 10-14 days (Cook, 2000a). In chickens the 
symptomatology is generally milder than turkeys, nevertheless the disease can be 
exacerbate by secondary bacterial infection. Co-infection with E. coli can lead to 
the Swollen Head Syndrome (SHS): not only respiratory signs characterize this 
disease, but it’s also present a general head swelling, causing neurological signs, 
such as disorientation, torticollis and opistothonus (Hafez, 1993; Jones et al., 1991). 
In both the species, AMPV infection can cause drop in egg production. In turkeys 
the drops in eggs production can reach even 70%, but generally it assets between 
10% and 20% (Schiricke, 1984; Wyeth, 1990). Associated with the drop of the eggs 
production, it’s usually observed a decrease in the quality of the eggs shell (Drouin 
et al., 1985). Drops in egg production have been reported in field in laying hens too, 
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ranging from 2% to 40% in association with poor egg quality (Drouin et al., 1985; 
O’Brian, 1985; Picault, 1988). Nevertheless in experimental conditions only the 
injection of virus is able to decrease the laying performance in chickens (Cook et 
al., 2000; Hess et al., 2004; Sugiyama et al., 2006).  
 
Figura 2.3 Swollen head syndrome in chicken 
 
2.1.5 POST-MORTEM 
2.1.5.1 Gross lesions 
In turkey has been observed an inflammatory case of the first respiratory tract 
including the presence of watery to mucoid exudate. It has also been observed 
welling of the infraorbital sinus caused by accumulation of mucus, conjunctivitis 
and submandibular oedema (Stuart, 1989).  In breeders, along with the lesion of the 
respiratory tract, may be seen prolapsed oviducts, folded shell membrane in the 
reproductive tract and egg peritonitis (Jones et al., 1988; Jones et al., 1991). In case 
of bacterial co-infections the clinical case can be more severe and airsacculitis, 
pericarditis, perihepatitis and pneumonia may be seen (Stuart, 1989). In chickens 
the lesions tend to be similar, but milder in the absence of bacterial co-infection 
(Catelli et al., 1998). E. coli co-infection can lead to rhinitis and sinusitis mucoid 
purulent exudate, infraorbital oedema, airsacculitis, pericarditis and accumulation 
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of a yellow gelatinous or even purulent oedema in the subcutaneous tissues of head 
and neck (Al-Ankari et al., 2001; Picault et al., 1987).  
 
2.1.5.2 Microscopic lesions 
The main histological lesions observed during AMPV infections are borne to the 
cells of the respiratory epithelium and no differences have been observed between 
turkeys and chickens. In the epithelial cells can be observed eciliation, 
deepithelization, and thickening of the mucosa, hyperaemia, mononuclear 
infiltration and glandular proliferation in the turbinates, infraorbital sinuses and 
trachea. The process of recovery of the epithelial tissue begins 14 d.p.i., while the 
fully recovery is reach between 18 and 21 d.p.i. (Aung et al., 2008; Catelli et al., 
1998). In the Swollen head syndrome, a part from the lesions listed above, have 
been reported periostitis, otitis and meningitis (Hafez, 1993). Epithelial damage of 
the oviduct has also been seen in both the species (Cook el al., 2000). 
 
 
Figure 2.4. Microscopic lesions in the trachea due to AMPV infection 
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2.1.6 IMMUNE RESPONSE 
As most of the respiratory pathologies, local immunity plays a central role in the 
prevention of the infection: in experimental condition has been observed a 
lymphocyte proliferation of the first respiratory tract and in the Harden’s gland, 
resulting in an increase levels of IgA and IgG in the tears and in the trachea (Cha et 
al., 2006; Liman and Rautenschlein, 2007; Rautenschlein et al., 2011; Sharma et al., 
2002;). However, the local immunity response doesn’t last long, explaining 
recurrent infections during bird’s productive life in farms (Rautenschlein et al., 
2011). Considering the systemic immunity, the cellular mediate immunity is also 
critical for the response to the infection, while the humoral response seems not to 
be. As suggested by experimental studies and field evidences, circulating antibody 
titres do not seem to be an indicator of protection: turkeys with no detectable 
antibody titres resulted to be protected against a virulent strain challenge (Cook et 
al., 1989; Rautenschlein et al., 2011).  Maternal immunity cannot prevent the 
infection, however chicks with high level of maternal antibodies showed milder 
symptoms compare to chicks without any maternal antibodies (Naylor et al., 1997a). 
More important, maternal immunity does not affect early vaccination, allowing 
young chicks to be immunized in early stages or directly in ovo (Cook et al., 1989; 
Worthington et al., 2003). It has been proven the interference of other viruses in the 
immunity response against AMPV: in particular the co-vaccination with vaccines 
against IBV or Newcastle disease virus (NDV) cause a significance decrease of 
AMPV antibody titre (Ganaphaty et al., 2006; Jones et al., 1998). 
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2.1.7 DIAGNOSIS 
AMPV clinical signs and post-mortem findings are too much similar to those of 
other respiratory pathogens, both viral and bacterial, not allowing a differential 
diagnosis. Thus the viral identification is crucial for the diagnosis. Isolating the 
virus, detecting the viral genome or proteins or demonstrating the specific 
serological response of the host could achieve the viral identification (Gough and 
Petersen, 2008).   
 
2.1.7.1 Virus isolation 
Virus isolation could be a difficult task, due to the short persistence of the virus in 
the host (Catelli et al., 1998; Cook et al., 1991). The time of the sampling, between 
3 and 5 d.p.i. from birds not yet showing any clinical signs, together with the 
conservation of the samples, are crucial factors for the virus isolation (Cook and 
Cavanagh, 2002). The primary isolation of AMPV could be done in 6 days old 
embryonated specific pathogens free (SPF) eggs via yolk inoculation or in tracheal 
organ colture (TOC) (Buys et al., 1989; McDougall and Cook, 1986; Panigrahy et 
al., 2000; Wyeth el al., 1986). After several passages the presence of embryonic 
haemorrhages, or in last instance the death of the embryo, are signs of positive 
isolation of the virus (Buys et al., 1989; Cook et al., 1999). After inoculation in TOC 
the presence of the virus is demonstrated by the ciliostatic effect between 3 and 5 
days post inoculation (Cook et al., 1991). TOC seems to be the most convenient 
isolation method, having a better sensitivity and being faster and cheaper compare 
to embryonate eggs isolation (Naylor and Jones 1993). However, this method is not 
suitable for subtype C isolation, because this subtype is not ciliostatic (Cook et al., 
1999). Once isolated, the virus could be adapted to several cell lines, such as VERO 
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cell, chick embryo fibroblast and chick embryo liver cell monolayer (Buys et al., 
1989; Grant et al., 1987; Williams et al., 1991). However, the embryo 
haemorrhages, the ciliostatic effect and the cytopathic effect (CPE) are specific but 
not exclusive of AMPV, therefore the identification of the virus needs to be 
investigate further using other methodologies, such as immunofluorescence (Jones 
et al., 1988), immunoperoxidase (Catelli et al., 1998), RT-PCR (Dani et al., 1999; 
Juhasz and Easton, 1994; Naylor et al., 1997a).  
 
2.1.7.2 Viral detection 
A faster and easier approach for the detection of the virus is the used of 
immunohistochemistry techniques such as Immunofluorescence (IF) and 
Immunoperoxidase (IP)(Catelli et al., 1998; Jones et al., 1988). The used of 
monoclonal antibodies allowed the differentiation between the different subtypes 
(Collins et al., 1993; Cook et al., 2003). However, these techniques are now a day 
overcome by molecular biology techniques, such as RT-PCR. RT-PCR, amplifying 
a region of the viral genome, showed to be very suitable for diagnosis, being fast, 
sensitive and reproducible (Gough and Jones, 2008). Moreover, due to its high 
sensitivity, the RT-PCR is able to detect virus for a longer period compare to the 
techniques mentioned before (Cook and Cavanagh, 2002). Several RT-PCRs have 
been developed, targeting different AMPV genes, showing different sensitivity and 
subtype specificity: a protocol targeting the highly conserved region of the N gene, 
has shown to be able to detect all the four subtypes, but not to differentiate between 
them (Bayon-Auboyer et al., 1999). RT-PCR targeting the F and the G gene enabled 
the differentiation of subtypes A and B (Jing et al., 1993; Mase et al., 1996; Naylor 
et al., 1997b).  Similar protocols were developed to differentiate subtype C from the 
other subtypes (Ali and Reynolds, 1999; Pedersen et al., 2000). Furthermore, has 
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been developed a multiplex RT-PCR protocol able to detect AMPV and other 
respiratory RNA viruses as avian influenza (AI), IBV and NDV (Ali and Reybolds, 
2000; Gorashi et al., 2007; Malik et al., 2004). Recently has been developed a RT-
PCR protocol, followed by endonuclease restriction analysis, able to differentiate 
between vaccine and field strains (Listorti et al., 2014). The advent of the Real Time 
PCR allowed a further step forward in AMPV detection: in recent years Real Time 
RT-PCR protocols able not only to detect and differentiate the virus with a better 
sensitivity, but also to obtain a viral quantification have been developed (Cecchianto 
et al., 2013; Cecchinato et al., 2014; Guioine et al., 2007). The virus could be also 
identified using serological tests, such as virus neutralization (VI), enzyme-linked 
immunosorbent assay (ELISA) and indirect immunofluorescence (IIF). Antibodies 
against AMPV persist in the sera up to 90 d.p.i., therefore these tests are very 
suitable to confirm the infection in field studies (Gough and Jones, 2008; Jones et 
al., 1988). Especially ELISA tests have shown to be very suitable for mass 
serological test. The lack of the ELISA test is that the efficiency is related to the 
coated antigen: this mean that homologous tests have shown good performance 
while heterologous test shown poor performance, leading even to false negative, as 
observed using A and B type ELISA to detected antibodies against the C type (Cook 
et al., 1999; Cook and Cavanagh, 2002; Maherchandani et al., 2005; Mekkes and de 
Witt, 1998; Toquin et al., 1996). To avoid the subtype specificity of the ELISA test, 
in recent years blocking ELISA protocols have been developed (Catelli et al., 2001; 
Turpin et al., 2003).  
 
2.1.8 DISEASE CONTROL 
A specific therapy against AMPV, is not available, therefore is important to actuate 
a preventive approach in order to avoid the spread of the disease. Vaccination is the 
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key point of the preventive approach, in fact several kind of vaccines are available 
and largely used in commercial poultry. Live attenuated vaccines are generally 
administrated in the early stage of life of different categories of commercial poultry, 
by intranasal inoculation, eye-drop, spray or drinking water (Cook, 2000b; Gough 
and Jones, 2008). Dependently on the bird category, more than one vaccination is 
needed: e.g. for broiler the vaccination at early stages is generally enough to fully 
protect the birds thru their entire productive life, while in growing turkeys more 
vaccination are needed. The situation changes for laying bird; those animals require 
a vaccination using an inactivated vaccine just prior the onset of the lay, in order to 
avoid a decrease in eggs production (Cook et al., 1996a; Cook, 2000b). Cross 
protection between different subtypes has been observed; subtype A vaccine confer 
protection against the B type and the other way round. Nevertheless, subtype C 
vaccine cannot protect against subtype A and subtype B (Cook et al., 1995; Cook et 
al., 1999; Eteradossi et al., 1995; Toquin et al., 1996). The co-vaccination with live 
vaccines against respiratory viruses, such as IBV and NDV, has been shown to 
cause a decrease in AMPV vaccine replication (Cook et al., 2001; Ganapathy et al., 
2005; Ganapathy et al., 2006). In order to avoid this interference two routes have 
been followed: the first one involved the vaccination in ovo against IBV and the 
other one the development of new generation vaccines, such as recombinant 
vaccines and subunit vaccines (Falchieri et al., 2013; Hess et al., 2004; Hu et al., 
2011; Kapczynski and Sellers, 2003; Qingzhong et al., 1994; Tarpey et al., 2001; 
Tarpey and Huggins, 2007; Worthington et al., 2003). 
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2.2 REVERSE GENETICS LITERATURE REVIEW 
 
The development of reverse genetic (RG) techniques for non-segmented negative 
stranded (NNS) RNA viruses has been a big step forward in viral research. 
Generation of viruses derived from DNA copies (cDNA) of their genome has 
allowed scientists to study the effect of specific mutations on viral biology and to 
perform major sequence changes, such as deletion or genes addition (Conzelmann 
and Meyers, 1999; Conzelmann, 2003; Walpita et al., 2005). Since RG has been 
established, several NNS RNA recombinant viruses expressing exogenous genes 
have been generated to develop improved or multivalent vaccines (Neumann et al., 
2002; Sato et al., 2011). 
These viruses have been shown to be suitable candidate as vectors form several 
reason: integration of the foreign gene into the host genome is very unlikely, 
because NNS RNA virus do not replicate through DNA intermediates; 
recombination is an extremely rare event; the genome organization is quite simple, 
generally 5-11 proteins and genes, making manipulations easier; they grow to high 
titres and express high levels of proteins; they are able to induce strong humoral and 
cellular immune responses (Conzelmann and Meyers, 1999; Walpita et al., 2005); 
studies proved they’re able to accept and express foreign genes without mutations 
incurring over several passages (Mebastion et al., 1996; Schnell et al., 1996). 
A reverse genetics system for AMPV subtype A was developed for the first time in 
2004 by Naylor et al.. A full length (FL) cDNA of subtype A was cloned in a 
plasmid vector including a kanamicyn- resistant gene, essential in the cloning 
process, a T7 promoter and Hepatitis delta virus ribozyme (HDRV) (Naylor et al., 
2004). Similarly, the genes coding for the support proteins essential to form the 
ribonuclear complex (RNP), N, P, L and Matrix 2 (M2) were also cloned in other 
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plasmids lead by a T7 promoter (Naylor et al., 2004). VERO cell infected with a 
recombinant Fowlpox virus expressing the bacteriophage T7 polymerase were used 
as substrate for the viral rescue. The T7 polymerase expressed by the recombinant 
Fowlpox virus is able to recognize the T7 promoter inserted in the plasmids and 
then to initiate transcription directly from them, allowing the formation of the RNP 
(Naylor et al., 2004). After the complex has been established, genome replication 
and gene transcription can begin as occur naturally, producing new RNA virions. 
Two years later, a reverse genetics system was similarly developed in the USA for 
suntype C, but to date, the attempt to develop a reverse genetics system for subtype 
B failed (Govindarajan et al., 2006). The development of these systems allowed 
investigating further the behaviour of the virus, thru the insertion of multiple 
mutations (Brown et al., 2011; Naylor et al., 2007; Naylor et a., 2010) and genes 
deletion (Govindarajan et al., 2010; Ling et al., 2008; Whelan et al., 2004). More 
important, the AMPV reverse genetics systems have shown that the virus is able to 
accept and express exogenous genes, electing AMPV as vector for the development 
of recombinant live vaccines (Govinfarajan et al., 2006; Lupini et al., 2008). In 2013 
Falchieri et al., demonstrated that AMPV-A is able to accept and express infectious 
bronchitis virus (IBV) exogenous genes and to induce a partial protection at the 
challenge. 
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3. GENERAL MATERIALS AND METHODS 
 
In this chapter are described the general materials and methods used throughout the 
studies. Any deviations from the materials and methods described below will be 
specified in the following chapter. 
 
3.1 Nucleic acid extraction 
3.1.1 Viral RNA was extracted and purified using Qiamp viral RNA mini kit 
(Qiagene), following the manufacturer recommendation. 
3.1.2 Plasmid DNA was extracted and purified using Qiamp viral miniprep mini kit 
(Qiagene), following the manufacturer recommendation. 
 
3.2 Reverse transcription 
Reverse transcription of genomic viral RNA or mRNA was performed using Super 
ScriptTM III Reverse Transcriptase (Invitrogene). The enzyme was always added at 
the reaction mix at 50°C in order to avoid mispriming. 
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RT reaction mix 
Reagent  Quantity 
5 x First-Strand Buffer  4μl 
DTT (0.1M)   2μl 
dNTP solution (40mM)  1μl 
primer (10μM)  1μl 
Extracted RNA  2μl 
Rnasin (Promega) 0.5μl 
Water (Invitrogen) up to 20μl 
Mineral oil (Sigma) 50μl 
Super ScriptTM III (200u/ μl) 1μl 
Table 3.1 Reaction mix used to reverse transcribed the viral RNA.  
 
 
RT cycle 
Temperature Duration 
70°C 1 minute 
50°c 2 minutes 
50°c Hot Start 
50°C 90 minutes 
94°C 10 minutes 
12°C Hold 
Table 3.2 Cycle used to transcribed the viral RNA. 
 
 
3.3 Polymerase chain reaction 
In the studies were used different polymerases depending upon the required 
amplicon size and the following applications. The PCR products to be used in site 
directed mutagenesis (SDM) and ligation were generated using PfuTurbo DNA 
polymerase (Agilent Technologies). The short screening PCRs and sequencing 
PCRs were performed using GoTaq Flexi DNA polymerase (Promega). To avoid 
mispriming, Pfu Turbo was added to the reactions mix at 80oC.  
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Pfu Turbo reaction mix 
Reagents Quantity 
10X Buffer 5μl 
dNTP solution (40mM) 1μl 
Forward primer (10μlM) 1μl 
Reverse primer (10μM) 1μl 
Template 1μl to 5μl 
Pfu Turbo DNA Polymerase (2.5u/μl) 1μl 
Water (Invitrogen) Up to 50μl 
Mineral oil (Sigma) 50μl 
Table 3.3 Reaction mix used to amplify DNA or cDNA to be used in SDMs or ligations. 
 
 
Pfu Turbo cycle 
Temperature Duration Number of cycle 
80°C 10 seconds 1 
80°C Hot start 1 
94°C 5 seconds 
5 50°C 20 seconds 
68°C 60 seconds per kb 
94°C 5 seconds 
25 
50°C 20 seconds 
68°C 60 seconds per kb with 10 seconds time 
incremented 
12°C Hold  
Table 3.4 Amplification cycle used to amplify DNA or cDNA to be used in SDMs of ligations. 
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GoTaq reaction mix 
Reagents Quantity 
5X Go Taq Flexi Buffer 10μl 
MgCl2 solution (25mM) 3.5μl 
dNTP solution (40mM) 1μl 
Forward primer (10μlM) 1μl 
Reverse primer (10μM) 1μl 
Template 2μl 
GoTaq DNA Polymerase (5U/μl) 0.25μl 
Water (Invitrogen) Up to 50μl 
Mineral oil (Sigma) 50μl 
Table 3.5 Reaction mix used for the short screening PCR and sequencing.  
 
GoTaq cycle 
Temperature Duration Number of cycle 
94°C 15 seconds 1 
94°C 10 seconds 
35 50°C 20 seconds 
68°C 40 seconds  
12°C Hold  
Table 3.6 Cycle used for the short screening PCR. 
 
3.4 Agarose gel electrophoresis 
To visualise the PCR products, the SDM products, to check the integrity of the 
plasmids and to quantify them, was used agarose gel electrophoresis. Depending on 
the size of the bands to be visualised, the gel were prepared with concentrations 
ranging from 0.8% to 2% w/v using TBE buffer (Invitrogen) diluted 10 times added 
with Red Safe Nucleic Acid staining solution (Intron Biotechnology) to visualized 
the bands under U.V. light. 5 to 10μl of each sample, depending on the nature, were 
mixed with 5μl of loading buffer and then loaded onto the gel. In each run molecular 
weight markers HyperLadder I (Bioline) was included: this weight markers enable 
DNA quantification.  
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3.5 Sequencing 
Before the sequencing all the PCR products were purified using Shrimp Alkaline 
Phosphatase (SAP) (Usb) and Exonuclease I (EXO) (Usb) to dephosphorylate and 
degrade residual dNTPs and primers. The purified amplicons were submitted to 
Source Bioscience Sequencing (Cambridge UK). The sequences were then 
visualised using Chromas, aligned and analysed using both Bioedit Sequence 
Alignament Editor and Generunner. 
 
3.6 Ligations 
XhoI and SalI are two restriction enzymes (RE), which recognise to different site, 
although they both create the same 5’ overhang. After digestion the two different 
sites can be ligated. This leads to a sequence that does not contain the complete 
recognition sequences of either RE and therefore cannot be digested by them. These 
features have been used in these studies to circularised plasmids and to ligate PCR 
products into plasmids. All the ligations, were performed using T4 DNA ligase 
(Fermentas) in the presence of the XhoI (Invitrogen) and SalI (Invitrogen): the 
ligation mixtures were incubated at 14°C for at minimum 2 hour. 
 
Ligation reaction mix 
Reagents Quantity 
5X Ligation Buffer 2μl 
XhoI (10u/μl) 0.5μl 
SalI (15u/μl) 0.5μl 
Plasmid 0.5μl to 2μl 
Amplicon 1μl to 5μl 
T4 DNA ligase (30u/μl) 0.5μl 
Water (Invitrogen) Up to 20μl 
Table 3.7 Reaction mix used to cicularised plasmids and to ligate PCR products into plasmids. 
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3.7 Site directed mutagenesis  
Site directed mutagenesis (SDM) was performed both using primer pairs and blunt-
end PCR products, also called megaprimers. The technique has been used to 
introduce useful point mutations, multiple nucleotide substitution or exogenous 
genes. All SDMs were performed using PfuTurbo DNA polymerase (Agilent 
Technologies) as enzyme. 
 
 
Pfu Turbo reaction mix 
Reagents Quantity 
10X Buffer 5μl 
dNTP solution (40mM) 1μl 
Forward primer (10μlM) 1μl 
Reverse primer (10μM) 1μl 
Plasmid template 1μl to 5μl 
Pfu Turbo DNA Polymerase (2.5u/μl) 1μl 
Water (Invitrogen) Up to 50μl 
Mineral oil (Sigma) 50μl 
Table 3.8 Reaction mix used in SDM reactions. 
 
If megaprimers were used in the SDM, a 5μl volume of the amplicons was added to 
the reaction mix. 
 
Pfu Turbo cycle 
Temperature Duration Number of cycle 
80°C 10 seconds 1 
80°C Hot start 1 
94°C 30 seconds 1 
94°C 30 seconds 
18 50°C 60 seconds 
68°C 30 minutes 
12°C Hold  
Table 3.9 Cycle used in SDM reactions. 
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Each SDM product was treated with DpnI (Agilent) enzyme in order to remove the 
original methylated plasmids. 10μl of the SDMs were incubated at 37°C for at 
minimum 2 hours with 1μl of DpnI (10u/μl), followed by a step at 60°C for 20 
minutes to inactivate the enzyme. 
 
3.8 Transformation and liquid culture 
All transformations were carried on using Max Efficiency STB12 Competent Cells 
(Invitrogene). The transformation protocol adopted is the following: 1μl of SDMs 
or ligations products was gently added to about 100μl of STB12 cells and incubated 
for 30 minutes in ice, then heat shocked at 42°C in water bath for 25 seconds and 
eventually for further 2 minutes in ice. 250μl of SOC medium was then added to the 
transformation mixture and the samples were agitated and incubated at 25°C for 90 
minutes. After the incubation the whole volume of each transformation mixture was 
inoculated onto LB agar plates, added with Kanamycin antibiotic at a concentration 
of 15μg/ml and incubated for 24 to 72 hours at 25°C. Positively transformed cells 
carried the plasmid Kanamycin resistance gene, allowing them to grow in the 
presence of that antibiotic. Colonies were screened by PCR and the positives were 
liquid cultured in 15ml LB broth (Gibco) containing Kanamycin at a concentration 
of 15μg/ml. Liquid cultures were agitated and incubated at 25°C for 24 up to 72 
hours.  
 
3.9 Restriction enzyme digestion 
Restriction enzymes were used in these studies for two different purposes: 1- 
plasmid DNA mapping and quantification, 2- preparation of PCR products and 
plasmids DNA for sticky ends ligation. For the first purpose were used EcoRI 
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(Invitrogen), for the second one XhoI and SalI. All restriction enzyme mixtures were 
incubated 2 hours at 37°C, following manufacture recommendation. 
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4. A COMPARISON OF AMPV SUBTYPE A AND B FULL 
GENOMES, GENE TRANSCRIPTS AND PROTEINS LED TO 
REVERSE GENETICS SYSTEMS RESCUING BOTH 
SUBTYPES. 
 
4.1 INTRODUCTION 
 
Avian rhinotracheitis is a major disease affecting domestic poultry throughout most 
of the world and is caused by infection with avian metapneumovirus (AMPV). Four 
AMPV subtypes (A to D) have been discovered and of these subtypes A and B are 
considered responsible for most AMPV related disease in chickens and turkeys 
outside of the USA. The extensive use of live vaccines of both A and B subtypes 
has made it difficult to accurately assess the relative prevalence of each subtype in 
the field in many world regions, but nonetheless subtype B field strains are generally 
accepted to be dominant in Western Europe, and for this reason, vaccination with 
this subtype has been prioritised (Cecchinato et al., 2014). 
For more than ten years, the availability of subtype A reverse genetics (RG) systems 
(Ling et al., 2008; Naylor et al., 2004) has allowed subtype A virus genomes to be 
modified and the resultant phenotypes investigated. Within suitable cells, full length 
DNA viral copies, transcribed to RNA in the presence of a number of essential 
AMPV proteins, produce the remaining viral proteins, then viruses with sequences 
matching the genome copy. Using this RG tool, effects of some precise genetic 
changes on virus properties have been determined, in terms of gene deletions (Ling 
et al., 2008; Naylor et al., 2004), virulence (Brown et al., 2011), protective capacity 
of live vaccines (Naylor et al., 2010) and gene insertions (Falchieri et al., 2013). 
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Generally in mononegavirales reverse genetics systems, the viral polymerase 
replicates N protein encapsidated RNA antigenome in association with the P 
protein, and for the family Pneumovirus transcription factor M2 protein, as has been 
reviewed previously for similar viruses (Whelan et al., 2004).  Specific genome 
sequences are known to be involved in regulation of polymerase attachment, 
genome replication, transcription initiation, transcription termination and the 
balance of genome and antigenome copies, but for AMPV most details of these 
sequences remain unknown.  For genome replication, the viral polymerase must 
recognise replication signals but ignore transcription start/stop signals, whereas for 
transcription, these signals must be recognised.  
Comparison of complete genome sequences has shown that subgroups A, B and D 
are more related to each other than subtype C (Brown et al., 2014) and another 
comparison of subtypes A, B and C showed subtype A and B to have the most 
similar genomes (Jacobs et al., 2003). Subtypes A and B also appear to be most 
similar in their species specificity and behaviours in the field, hence live subtype A 
and B vaccines have been employed largely interchangeably to control disease in 
commercial turkeys and chickens, albeit with an increasing  bias toward subtype B. 
Cross protection and antigenic studies have suggested that some protective and 
antigenic differences do exist  (Collins et al., 1993; Cook et al., 1993; Van de Zande 
et al., 2000) and this highlighted the need for a reverse genetics system to enable 
the generation of improved live subtype B vaccines, as well as to understand other 
properties of this subtype.  
A project to develop a subtype B reverse genetics system was initiated in our 
laboratory soon after the subtype A development (Naylor et al., 2004) but 
encountered problems. Also at a similar time other groups were known to have 
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initiated similar ventures yet no system was forthcoming. In our case this was due 
to problems encountered while attempting to clone larger subtype B genome 
sections into the plasmids previously found successful for cloning subtype A 
viruses. While N, P and M2 genes could be readily cloned, the L gene and full 
genome proved impossible, as sequences proved toxic even using the specialist 
tolerant cloning bacteria previously found adequate for subtype A. This either led 
to the complete absence of clones, or clones containing major deletions, often of 
several thousand nucleotides. 
With a view to potentially utilising some of the available subtype A RG system 
components in the development of a subtype B system, it was decided to investigate 
properties of subtype A and B viruses likely to affect rescue and replication. Leader 
and trailer sequences essential for attachment of the viral polymerase were 
determined and compared, as were those sequences recognised by the viral 
polymerase in initiating and terminating the transcription of individual viral genes.  
The study further compared protein similarities, especially for N, P, M2 and L which 
are all directly involved in encapsidation, replication and transcription of the 
genome in a reverse genetics system. In most cases we report for the first time the 
individual gene transcription stop signals for both subtype A and B virus genes, as 
well as many previously unreported leader and trailer sequences.  While many gene 
stop sequences were predictable from available genome sequences, others were not, 
especially where more than one termination like sequence was present at a gene 
end, as for example seen with the M2 and G genes. When combined, results of these 
studies suggested that subtype A and B reverse genetics systems might be able to 
recover full genome copies of the opposite subtype. Due to the importance of 
AMPV subtype C in North America and elsewhere, comparison included an 
established virus from that subtype.   
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During the investigation cloning attempts were continued and during these, a 
literature search brought to our awareness a commercial plasmid pSMART that had 
permitted problematic regions of an influenza virus genome to be successfully 
cloned (Zhou et al., 2011). This was applied in cloning the subtype B full genome 
and L gene.  Finally a subtype B cloned genome was rescued with either subtype A 
or B support components, hence this study includes report of the first AMPV 
subtype B reverse genetics system. We also demonstrated the rescue of a subtype A 
virus using this subtype B reverse genetics system. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Viruses 
The subtype A ( Germany A) virus used to create the first AMPV reverse genetics 
system was isolated in Germany in the 1990’s (Naylor et al., 2004) and was later 
tested in vaccination studies (Naylor et al., 2010). Other subtype A field viruses 
sequenced for gene sequence comparison were #8544(Jones et al., 1986), Italy 259 
(Cecchinato et al., 2010), UK 3B (Mcdougall & Cook, 1986), CVL 14-1 (Collins 
& Gough, 1988) and UK CP/1 (Jones et al., 1991); and commercial live vaccines 
Poulvac TRT (Fort Dodge), Nobilis TRT (Intervet) and Turkadin (discontinued). 
The subtype B virus used to create the first AMPV subtype B reverse genetics 
system was a vaccine strain derived from UK strain 11/94. Subtype B field viruses 
sequenced for gene sequence comparison were Italy 205 and 240 (Cecchinato et al., 
2010), France 147 and 38 (Cook et al., 1993), Netherlands 27 (Cook et al., 1993), 
Italy 16-91(Cook et al., 1993); and commercial live vaccines Nemovac (Merial), 
Aviffa (Merial) and Nobilis Rhino CV (Intervet). 
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4.2.2 Determination of leader and trailer sequences 
RNA of subtype A was extracted from from #8544, Poulvac TRT, Italy 240, 
RhinoCV, Nemovac  and from some recombinant rescued viruses using QIAamp 
Viral RNA mini kit (Qiagen, France, Courtaboeuf) according to the manufacturer’s 
instructions (3.1).  
Leader and trailer were determined by 3’RACE on the genome and antigenome 
respectively following the protocol described by Brown et al. (2013). Briefly: the 
viral negative sense RNA genome and positive sense replication intermediate were 
poly A tailed by incubation with E-PAP Poly(A) tailing polymerase (Ambion 
Invitrogen France, Illkirch) at 37 degrees for 1hour. The poly A tailed RNAs were 
purified using NucAway spin columns (Ambion: Invitrogen France, Illkirch) 
according to manufacturer’s recommendations. Reverse transcription (3.2) was 
performed using a mixture of 3 primers each starting with an adaptor sequence of 
19 base pair at the 5′ end followed by 21 bases complementary to the poly A tail 
and finally an anchor base at the 3′ end (the primers differ only in the bases used as 
anchor). The ends of the cDNAs of the genome and the positive sense replication 
intermediate were amplified by PCR (3.3), using a primer of the same sense as the 
adaptor sequence and one subtype specific reverse primer for the 3′ end and a 
subtype specific forward primer for the 5′ end. The amplicons were sequenced and 
the analyses (3.5). Primers listed in table 4.1. 
 
4.2.3 Determination of 3’ termini sequence of subtype A and B AMPV mRNAs 
RNA of the viruses listed in the previuos chapter was extracted using QIAamp Viral 
RNA mini kit (Qiagen, France, Courtaboeuf) according to the manufacturer’s 
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instructions (3.1). The mRNA was amplified by RT-PCR using a method described 
by Brown et al. (2011). The mRNA was reverse transcribed (3.2) using a mixture 
of 3 primers each starting with an adaptor sequence of 19 base pair at the 5′ end 
followed by 21 bases complementary to the poly A tail and finally an anchor base 
at the 3′ end (the primers differ only in the bases used as anchor). The cDNAs were 
then amplified by PCR (3.3) using a gene specific forward primer and a primer 
matching the adaptor. The PCR products were sequenced toward the polyA tail 
using the same gene specific primers. The sequences obtained were aligned and 
analysed (3.5). Primers listed in table 4.1. 
 
4.2.4 Determination of viral gene sequences and their comparison 
Sequences of subtype A and B virus genes were as determined by sequencing of 
PCR amplified genome sections, as described in previous studies (Brown et al., 
2011; Cecchinato et al., 2010; Naylor et al., 2004; Naylor et al., 2007). Using 
Bioedit, nucleotide sequences aligned and inter-subtype identities calculated, then 
sequences were translated to allow predicted amino acid identities and similarities 
to be calculated. 
 
4.2.5 Construction of subtype B reverse genetics system 
4.2.5.1 Preparation of pSMART plasmid vector 
pSMART vector was used to clone the AMPV-B FL genome copy. Prior the 
cloning, the vector have been phosphorylated, using T4 polynucleotide kinase 
(Promega), following the manufacturer recommendation, ligated (3.6) and 
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transformed on E. coli competent cells (3.9). An XhoI site was eventually 
introduced by SDM (3.7) to allow the ligation of the AMPV-B amplicons. 
 
4.2.5.2 Subtype B genome copy construction 
To generate the avian matapneumovirus (AMPV) subtype B DNA full genome copy 
was adopted a strategy based on a series of RT-PCR, SDM and ligation steps (Figure 
4.1). 
RNA was extracted from a RhinoCV (Intervet) vaccine (3.1). Two overlapping 
cDNA sequences were obtained by reverse transcription (3.2) and the cDNA was 
used as template for three PCRs (3.3) in order to cover the AMPV-B genome 
sequence from the leader to position 12.0kb (3.3). The amplicons, 0-4kb, 4kb-8kb, 
8kb-12kb, were generated using primers listed in table 4.2 that introduce SalI site at 
each end of the products. The primers to generate the leader of the genome contain 
a T7 promoter sequence at the 5’ end. The last section of the genome was copied by 
high fidelity PCR (3.3) from a plasmid containing the AMPV-B sequence from 
position 12.0kb to 13.5kb and the sequence of the Hepatitis Delta Virus Ribozyme 
(HDVR).  
8kb-12kb amplicon was ligated into the modified pSMART plasmid (3.6). The 
plasmids were transformed (3.8) and the colonies screened by PCR (3.3) using 
primers chosen at either side of the junction. Colonies positive at the screening were 
cultured on LB Broth (3.8), the plasmids purified (3.1) and checked for integrity by 
restriction endonuclease (RE) analysis (3.9). The generated plasmids underwent 
SDM (3.7) to introduce an XhoI site at the 12kb end. The XhoI site was used to 
ligate the 12.1kb-13.5kb product (3.7). Following the same protocol the 4-kb-8kb 
and then the 0-4kb amplicons were cloned into the plasmids, as showed in figure 
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4.1. The full-length (FL) plasmids generated were sequenced (3.5). The sequences 
obtain were aligned against RhinoCV one (3.5). 
 
4.2.5.3 Preparation of B type support plasmids 
N, P and M2 sequences were amplified by RT-PCR from RhinoCV vaccine. The 
RNA was extracted (3.1), reverse transcribed (3.2) and amplified using high fidelity 
polymerase (3.3). Amplicons were cloned into the same plasmids as had been used 
previously in the subtype A rescue system (Naylor et al., 2004). For the L gene, 
because of cloning stability issues with the original plasmid used to clone the 
subtype A L, it was copied by hi-fidelity PCR (3.3) from the cloned full subtype B 
genome to include the pSMART LC Kan sequence. This was ligated (3.6) and 
cloned (3.8). The plasmids generated were cut with RE to check for integrity (3.9) 
and sequenced (3.5). 
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RT primers 
Primer Sequence 
Dta-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTA  
Dtc-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTC  
Dtg-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTG 
Adaptor 
Adaptneg GCATCTCGAGGCTTGTGGCT 
PCR and sequencing primers subtype A 
Gene Primer Sequence 
Leader N 2-  GCATGCCTACCTCTGCTG 
N N 1+ CAATATAATGTTGGGCCATG 
P P 1+ GCAATGATAGGGATGAGA 
M M 7+ GAAGCCATATGGTATGGTCTC 
F F 3+ GTGTGAGTTGCTCCATTGG 
M2 M2:4+ GTCTCCCAGAGAAAAACT 
SH SH 2+ GCAACTAAGTGCTGCTAC 
G G 7+ GAAAAGACATTCAGTACATAC 
L L 10+ GGGAGTAAACTATCAGGATCGG 
Trailer L 19+A GAAGTGGTTAAATCACGTTCTG 
PCR and sequencing primers subtype B 
Gene Primer Sequence 
Leader N 2- GCATGCCTACCTCTGCTG 
N NAB 1+ TCAAATACCCAAGAACCAAAAGCCGTC 
P PAB 1+ CCGACCCTGACGAAGATAATGATG 
M B 2.28+ CTGCTGGACCAGCTAAAAACTC 
F FAB 2+ ATGACTATGTGTTCTGTGATACTGCAGC 
M2 M2AB 1+ GAATCCAGCAAATCTCATAAACAGTCTCAAG 
SH SHAB 1+ CAGAGCTGAGCACAACTACAGC 
G G15+B GCAAGACGACCGACCAGAGAC 
L LAB 12+ CACAGCTCCTTGCTATGGAGAGG 
Trailer B 13.15+ CAAACCTAACACACTTGGACAACTCC 
Table 4.1 Primers used to determine leader, trailer and transcriprion stop sequences 
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Primer Sequence 
pSMART Xho + CCTGAATGATATCAAGCTTGAATTCCTCGAGGAATTCTCTAGATAT
CGCTCAATACTG 
pSMART Xho - CAGTATTGAGCGATATCTAGAGAATTCCTCGAGGAATTCAAGCTT
GATATCATTCAGG 
RT Primer 
Fragments Primer Sequence 
0-8kb B 8.38 neg GAGCACTCTTCCTGTTTTCTCCAACAAAC 
8kb-12.0kb LAB 1+ CTGGAAGTGTCACAGACCAGTGC 
PCR Primer 
Fragments  Primer Sequence 
0kb-4kb APV lead T7 
Sal+ 
GTCGACTAATACGACTCACTATAGGGACGAGAAAAAAAACGC 
B 4.0 Sal- TAAGTCGACGTTGATATGTTTTGGTTGC 
4kb-8kb B 4.0 Sal+ CATATCAACGTCGACTTACCCTTGCAAAG 
B 8.08 Sal- AAACTCGTTGGTCGACTCCTAAATCG 
8kb-12.1kb B 8.08 Sal+ AAACTCGTTGGTCGACTCCTAAATCG 
AVIF 12.1 Sal- GTCATAGCATGTCGACTGTCTGAGTAAC 
12.1kb-13-
5kb 
AVIF 12.1 Sal+ GTTACTCAGACAGTCGACATGCTATGAC 
CTPE 110 Sal+ CTTCCCCGTCGACGATGTCGGCG 
SDM Primes 
Position Primer Sequence 
Psmart 
cloning site 
Psmart 220 
Xho+ CGTCTTGCTCAAGGCCGCGATTAAATT 
Psmart 220 Xho- AATTTAATCGCGGCCTTGAGCAAGACG 
4.0kb B 4.0 Xho+ GCAGTGCAACTCGAGCATATCAAC 
B 4.0 Xho- GTTGATATGCYCGAGTTGCACTGC 
8.0kb B 8.08 Xho+ CTAGGACTCGAGAGCAAACTCGTT 
B 8.08 Xho- AACGAGTTTGCTCTCGAGTCCTAG 
12.1kb AVIF 12.1 Xho+ GTTACTCAGACACTCGAGATGCTATGAC 
AVIF 12.1 Xho- GTCATAGCATCTCGAGTGTCTGAGTAAC 
11542bp B 11542 + GAAGCAACTCAAATGCAGAGAGAATTGCAACTGAG 
B 11542 - CTCAGTTGCAATTCTCTCTGCATTTGAGTTGCTTC 
Table 4.2 Primers used to generate subtype B full genome copy 
 
RT Primer 
Gene Primer Sequence 
N and P Ac-Le-Trail + ACGAGAAAAAAACGC 
M2 FAB 1+ GCTAAAACAATAAGATTAGAAGGGGAGGTG 
PCR Primer 
Gene Primer Sequence 
N N Start + B GTCTCTTGAAAGTATTAGGC 
NP 1.25- ACATTTTCACTTGTCCCGAATTTTTAATTACTC 
P P Start + B GTGAAAATGTCTTTCCCCGAAGGCAAG 
M 2.12- AGGACTCCATGTTTACTTGTCCC 
M2 M2 Start + B GACAAGTAAAGATGTCCAGAAGGAATCCCTG 
M2-1 end B- TTGCACCTAATTACTGCTGTCACCC 
L L Start + B GACCAATATGGACCCATCCAATGAG 
L end B- CTTTATGGTCTATTTTGTGCTCAGTATGTACC 
Table 4.3 Primers used to generate the support genes plasmids 
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Figure 4.1 Schematic representation of the strategy used to construct a clone DNA copy of subtype B virus. 
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4.2.6 Recovery of viruses 
Vero cells infected with a fowlpox recombinant virus expressing T7 polymerase 
were transfected initially with a cloned subtype A genome, together with subtype A 
support protein genes, and cloned subtype B support protein genes as they became 
available, using Lipofectamine 2000, under  the same conditions and concentrations 
previously used for subtype A rescue (Naylor et al., 2004). Subsequently the cloned 
subtype B genome replaced the subtype A genome. Eventually subtype B 
components entirely replaced those from subtype A. In addition a subtype B genome 
copy was used with only subtype A components. Details are given in Table 4.8. 
 
4.3 RESULTS 
 
4.3.1 Determination and comparison of leaders and trailers sequences 
Determined leader and trailer sequences are given in Table 4.4 and sequence 
chromatograms in Figure 4.2. For reference, leader and trailer sequences from a 
previously published subtype C virus are included in Table 4.4. For subtypes A and 
B, leaders or trailers sequences were always found to be in agreement for viruses 
within the same subtype. 
The leader sequences of subtype A and B viruses were identical for the first 12 
nucleotides and when compared to antigenomic trailer sequences, for subtype A 
they were identical for those first 12 nucleotides, whereas differences were found 
for subtype B. After position 12 similarities became minimal. 
For the trailer, an antigenomic sequence from nucleotides 13-21 GGCAUAAGU 
was detected in all 3 subtypes.   For all 3 subtypes the remaining 18-24 nucleotides 
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of the leader/trailer sequences up to the N start/L end were mainly comprised of 
apparently random Us and As and there was no obvious common sequence motif 
between the subtypes.  
The 2 GGs normally assumed to be added to the virus leader due to use of a T7 
promoter in RG derived viruses were never detected. 
 
4.3.2 Determination and comparison of gene start and stop sequences 
Determined mRNA sequence chromatograms for each gene are shown in Figure 
4.3.  Gene start and stop sequences for subtype A and B viruses are compared in 
Table 4.5 in genome sense (3’to 5’) and include sequences predicted from a 
previously determined published subtype C virus full genome (accession number 
AY579780). All genes started with the sequence 3’CCCUGUUCA5’ with the 
exception of F and SH genes of subtype B which started with 3’CCCCGUUCA5’. 
All gene stop signals started with UCA then had a variable sequence of generally 3 
to 5 nucleotides after which followed between four and seven Us (which became 
the polyA tail), with the exception of the subtype A SH gene which had an 11 
nucleotide separation but which still efficiently stopped transcription and led to 
polyadenylation. In the case of Germany A virus, sequence changes within this 11 
nucleotide region led to absence of detectable monocistronic SH mRNA. This 
absence of detectable SH gene transcription termination would be assumed to 
prevent downstream G expression (Naylor et al., 2007; Whelan et al., 2004). 
Otherwise the subtype A and B transcription stop sequences were very similar as 
shown in Table 4.5 with a consensus for subtype A of  
UCAAU(A/U)A(A/U)UUUU and subtype B of  UCAAUAU(A/U)UUUU. 
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AMPV 
subtype 
Leader and complimented trailer sequences  
for subtype A, B and C viruses 
  A leader 3’UGCUCUUUUUUUGCAUAAAUUCGUC…………N start 5’ 
  A trailer1  3’UGCUCUUUUUUUUGGCAUAAGUAGU…………L stop 5’ 
 
B Lead 3’UGCUCUUUUUUUGCGUAAGUUCAG…………N start 5’ 
  B trailer1 3’UGCCGUUUUUUUGGCAUAAGUUAU…………L stop 5’ 
 
2C leader 3’UGCUCUUUUUUUGCGUAUAUUCUG…………N start 5’ 
2C trailer1 3’UGCCGUUUUUUUGGCAUAAGUAGG…………L stop 5’ 
 
     
    1 Antigenome sequence 
    2 Not determined by the authors and based on accession AY579780 
 
    Table 4.4 Determined leader and trailer sequences for subtype A and B viruses, with published subtype C for reference 
1
 polyadenylated DNA copies of genomic sense leader 
2
 polyadenylated DNA copies of antigenome sense trailer 
3
Subtype A 
3
Subtype B 
Leader 
1
 
Trailer 
2
 
  3’ 5’ 
 3’ 5’ 
3’ 
3’ 
5’ 
5’ 
3
Sequence common for all viruses of this subtype 
Figure 4.2 Chromatograms of DNA copies of subtype A and B AMPV leader and trailer sequences 
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Subtype A
1
 Subtype B
1
 
Germany A 
N 
P 
M 
F 
M2 
G 
L 
SH 
2 
1
 Common terminal sequence found in all viruses sequenced except for subtype A, SH gene 
2
 No monocistronic SH mRNA. Sequence displayed shows the region of discistronic SH-G mRNA  
  Underlined sequences are common between all viruses sequenced except subtype A, SH gene Figure 4.3 Chromatograms of DNA copies of subtype A and B AMPV leader and trailer sequences 
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Gene AMPV 
subtype 
Sequence from transcription start to subsequent transcription start 
 
N  
A CCCUGUUCAGUUUU -ORF+NCGE- UCA UUAA2UUUUUUUAUA 
B CCCUGUUCAUUUU  -ORF+NCGE- UCA UUAA2UUUUUAAG  
C1 CCCUGUUCACUUU  -ORF+NCGE- UCA UUAAUUUUUUUAUA 
 
P  
A CCCUGUUCAUUGU  -ORF+NCGE- UCA AUAC2UUUUUUA 
B CCCUGUUCACUUU  -ORF+NCGE- UCA AUAC2UUUUUUA 
C1 CCCUGUUCAGUUU  -ORF+NCGE-  UCA AUUAUUUUUUG 
 
M  
A CCCUGUUCAGUUU  -ORF+NCGE- UCA GUUA2UUUUUUAA 
B CCCUGUUCAUUUG  -ORF+NCGE- UCA AAUUA2UUUUUUAUA 
C1 CCCUGUUCACCUU  -ORF+NCGE- UCA 
GUUCUAUUUGUGUCUCUCAUGUGAAUGGUUUAGUGUCAUU 
GUUAAAGCAAAAAUUGGGAGAGUAUCAAUAAUGGAUCGAACUAUAAUAAAUCUUUU
UUAA 
 
F 
A CCCUGUUCAUCC   -ORF+NCGE- UCA AUAAA2UUUUAA 
B CCCCGUUCAUUU   -ORF+NCGE- UCA AUGUA2UUUUUUCA 
C CCCUGUUCACUUU  -ORF+NCGE- UCA AUGAUUUUUUAA 
 
M2 
A CCCUGUUCACUUC  -ORF+NCGE- UCA AUUAA 
2UUUUGGUUAAUUCGAUAUUCAGGUUUUUUCCCA 
B CCCUGUUCAUUUC  -ORF+NCGE- UCA 
AUAUA2UUUUUGUUAACUCGUGGGGGGGGCUUUUUUCUA 
C1 CCCUGUUCACUUC  -ORF+NCGE- UCA AUUAUUUUUUAA 
 
SH 
A CCCUGUUCAGUAU  -ORF+NCGE- UCA UAAUAAAUUAA2UUUUUCUUUCCAG  
Germany 
A 
CCCUGUUCAGUAU  -ORF+NCGE- UCA UAAUAAAUAAAUGUUUCUUUCCAG 
did not stop 
B CCCCGUUCAGUUC  -ORF+NCGE- UCA AUUAA2UUUUAGUCUUCUG 
C1 CCCUGUUCAGUUG  -ORF+NCGE- UCA 
AUAAAUUUUUAGUACUUAUACAGACCUGUCACGGUUCCGGUUC 
UUUUUGGUUGUGCUCUUGUCCACUAGGUUACUAAUUUUUGCUAGUCUCUUCCUUUU
UG 
 
G 
A CCCUGUUCAUAGAGU-ORF+NCGE- UCA 
AUUGA2UUUUUACUUGUGUAUAUAUAGACUAUUAUUUUU 
UUGUGUAGUCUAUCAGAUUUUGUUAAUUUUCUUACUUUUGU 
B CCCUGUUCAUAGGUC-ORF+NCGE- UCA 
GUUA2UUUUUCAUUGGAAAGUGUAGAUUUUAUUUCGUUUU 
UCUUCUUUUUUCUUCUUUCUUCCUUUCUUUCUUCUUCUUAUCGUGUGUUGUCUUUC
CU 
C1 CCCUGUUCAGUUG  -ORF+NCGE- UCA AUUAAUUUUUCUU 
 
L 
A UCCUGGUUA      -ORF+NCGE- UCA AUUA2UUUUU to Trailer  
B CCCUGGUUA      -ORF+NCGE- UCA AUA2UUUUUU to Trailer  
C1 CCUGGUUCA      -ORF+NCGE- UCA AUAAAUUUUU to Trailer 
 
NCGE – non coding gene end 
1 Not determined by the authors and based on accession AY579780 
2 demonstrated start of polyadenylation in resulting mRNA  
 
Table 4.5 Determined consensus gene stop signals for subtype A and B viruses, with predicted subtype C sequences based on 
database reference 
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 Subtype A Subtype B Subtype C3 
Nucleotide position   A C G U  A C G U  A C G U  
1st 0 0 0 81 U2 0 0 0 8 U 0 0 0 8 U 
2nd 0 8 0 0 C 0 8 0 0 C 0 8 0 0 C 
3rd 8 0 0 0 A 8 0 0 0 A 8 0 0 0 A 
4th 5 1 0 2 A 6 0 1 1 A 6 0 1 1 A 
5th 1 0 0 7 U 1 0 0 7 U 0 0 0 8 U 
6th 4 0 0 4 A/U 4 0 1 3 A 3 0 1 4 U 
7th 5 1 1 1 A 3 1 0 4 U 7 1 0 0 A 
8th 4 0 0 4 A/U 4 0 0 4 A/U 3 0 0 5 U 
9th 1 0 0 7 U 0 0 0 8 U 1 0 0 7 U 
10th 1 0 0 7 U 0 0 0 8 U 0 0 0 8 U 
11th 0 0 0 8 U 0 0 0 8 U 0 0 0 8 U 
12th 1 0 0 7 U 0 0 0 8 U 0 0 0 8 U 
 
 
  1 Black shading identifies the majority nucleotide at the given position within the eight gene stop signals  
  2 Grey shading denotes the consensus stop signal for the given subtype   
  3 Not determined by the authors and based on accession AY579780 
 
Table 4.6 Determined consensus gene stop signals for subtype A and B viruses, with predicted subtype C sequences based on 
database reference 
 
4.3.3 Comparison of viral protein sequences 
Details of nucleotide identities, together with amino acid sequence identities and 
similarities for subtypes A, B and C are given for each gene in Table 4.7. 
Comparison of A, B and C sequences confirmed that subtype A and B proteins were 
more closely related to each other than they were to subtype C.  Between subtypes 
A and B, those proteins expressed from transfected cloned DNA in the reverse 
genetics system, N, P, M2 and L, had amino acid similarities of over 80%, and this 
was also the case for M and F. In contrast when comparing either subtypes A or B 
to subtype C, the similarity fell to approximately 79% in the case of the L gene. For 
the nonessential genes SH and G (Naylor et al., 2004), amino acid similarities 
between subtypes A and B were much lower at 60% and 46% respectively and fell 
to approximately half those values when SH and G of either subtype was compared 
to subtype C.   
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Gene  Subtype A vs B Subtype A vs C  Subtype B vs C 
Nuc aa nuc aa nuc aa 
N 761 912 973 66 70 87 68 71 87 
P 70 72 88 58 53 69 59 53 69 
M 75 90 98 70 78 91 72 78 91 
F 74 83 91 69 72 85 67 72 86 
M2 78 89 96 64 71 88 65 73 86 
SH 60 50 60 40 20 31 43 19 34 
G 53 36 46 28 10 17 29 12 20 
L 74 86 94 46 64 79 46 64 79 
Shading denotes greater than 80% identity/similarity 
1 nucleotide identity 
2 amino acid identity 
3 amino acid similarity 
 
Table 4.7 Nucleotide identities and predicted amino acid identities and similarities, comparing AMPV subtype A, B and C 
 
4.3.4 Construction of subtype B reverse genetics system 
4.3.4.1 pSMART plasmid vector preparation 
pSMART plasmid vector was successfully circularized, transformed and isolated, 
after being liquid cultured. PCR and restriction enzyme analysis confirmed that the 
XhoI site was added in the cloning region. 
 
4.3.4.2 AMPV-B full genome copy plasmids 
Three amplicons covering the first 12kb of the AMPV subtype B vaccine genome 
were successfully generated by RT-PCR. The amplicon covering the last 1.5kb of 
the genome was obtained by PCR from a plasmid containing also the Hepatitis Delta 
Virus Ribozyme (HDVR) sequence. Each amplicon generated was flanked by SalI 
site. 
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After a series of ligation steps several FL cDNA plasmids was generated, but only 
one of them showed the correct restriction endonuclease (RE) pattern. The mapping 
PCRs on the positive plasmid generated 11 amplicons of the expected size. The full 
genome sequence obtained was aligned against RhinoCV sequence and the analysis 
didn’t show any mutations. The plasmid was identified as vB. 
 
4.3.4.3 Support genes plasmids 
The amplicons of genes N, P, M2 and L were successfully obtained by RT-PCR or 
PCR and cloned into the same plasmids used for subtype A. Sequence analysis of 
the positive colonies showed that at least 1 plasmid per gene had the correct nucleic 
acid sequence. 
 
4.3.5 Recovery of virus from AMPV full length copies 
Combinations of cloned genes and genomes from both A and B subtypes are given 
in table 4.8, which shows that all combinations of subtype A and B components led 
to virus rescue. 
 
Rescue 
attempt  
Subtype B  
components 
Subtype A  
components 
Outcome 
1 N 
 
P M2 L genome Virus recovered  
2 N P M2 L genome Virus recovered 
 N P M2 L genome Virus recovered 
3 N P M2 genome L Virus recovered  
4 N P M2 L  genome  Virus recovered 
5 N P M2 L genome Virus recovered 
6 genome N P M2 L Virus recovered 
Table 4.8 Combinations of RG components used in virus rescue attempts and sucesfully rescued 
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4.4 DISCUSSION 
 
In order to overcome the issues previously faced in to establish a reverse genetics 
(RG) system for avian metapneumovirus (AMPV) subtype B, in the present study 
was initially performed a comparison of subtype A and B to assess whether subtype 
A components could be partially or fully substituted.  
Comparison of subtype A and B amino acid sequences of those proteins required 
for the RG system, N, M2 and L, showed very high levels of amino acid identity 
and similarity while P had a lower identity yet maintained 88% similarity. The 
fusion and matrix proteins were also highly similar. While SH and G genes identities 
were much lower, these genes are not required for virus replication in cell culture 
(Naylor et al., 2004) or turkeys (Naylor et al., 2010) so those differences were not 
considered an impediment to virus rescue.  The subtype C sequences were more 
different, having polymerase identities and similarities with subtype A and B 
viruses of 64% and 79% respectively. These data suggested that subtype A and B 
viruses might be recovered from subtype A or B full-length genome copies using 
either subtype A or B support proteins. It is not clear whether in spite of the greater 
differences found for the subtype C polymerase, subtype A and B reverse genetics 
components might still recover virus from subtype C full length copies.   
For similar viruses, the viral polymerase is known to recognise sequences in the 
leader and trailer which play a role in transcription, replication and genome 
encapsidation. (Whelan et al., 2004). The leader sequences of AMPV subtypes A, 
B and C and antigenome trailer of subtype A were identical for the first 12 
nucleotides, whereas subtype B and C trailers had a 2 nucleotide mismatch. Beyond 
nucleotide 12, virus leaders did not match their trailers and furthermore no common 
sequence motif was seen when comparing between subtypes. In contrast within the 
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antigenome trailers of all three subtypes between nucleotides 13-21, a sequence of 
3’GGCAUAAGU 5’ was found.  When later the NCBI database was searched for 
all available equivalent sequences (accession numbers HG934338 (subtype C, host 
duck), FJ 977568 (subtype C, host turkey), AB548428 (subtype B, host chicken), 
AY 590688 (subtype C host turkey)) this same sequence was always detected. 
While this sequence might be coincidental, it might also have some regulation role, 
perhaps in the replication of the antigenome copy in subtype A, B and C viruses.  
However further RG based studies would be required to substantiate such a 
hypotheses. But whatever the specific role of the sequence, or the extreme 12 
nucleotides of the leaders and trailer, the similarity across subtypes would appear 
compatible with the notion of a subtype independent RG system.   
Interestingly, while the use of a T7 promoter in the RG system would be expected 
to add two GG residues to the start of the antigenome copy which would be expected 
to be incorporated into the genome, and have sometimes been suspected of causing 
phenotypic differences between recombinant and original virus from which the 
DNA copy has been prepared, these were never detected.  We therefore conclude 
that these are edited out at an early stage of the RG rescue. This is a helpful practical 
observation because while the T7 promoter is very useful in RG systems, it is 
sometime avoided because of this perceived implicit sequence addition. 
A previously comprehensive minigenome investigation of gene start signal 
efficiencies showed that the CCCUGUUCA was most efficient and that the variant 
sequence of CCCCGUUCA found on subtype B SH and G proteins would be 
expected to reduce transcription of those genes (Edworthy & Easton, 2005). The L 
gene transcription start sequences  proved an exception and minigenome studies 
showed a reduced transcription efficiency (Edworthy & Easton, 2005), as might be 
expected for a gene coding a protein needed in smaller amounts.  Surprisingly gene 
starts of the otherwise more distantly related subtype C viruses (Brown et al., 2014) 
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like the subtype A viruses all used CCCUGUUCA, but again with the exception of 
the L gene. Clearly lack of gene start differences would means that gene start 
differences would not preclude a subtype independent RG system for AMPV. 
Transcription stop sequences had not been previously reported for most AMPV 
genes. In general the sequences found for AMPV subtype A and B were in 
agreement with those found previously for respiratory syncytial virus (Harmon et 
al., 2001). Nonetheless, a study of seven recombinant subtype A viruses, each 
containing a GFP reporter gene at different intergenic regions had shown that GFP 
expression did not follow the accepted model and suggested that inefficient genome 
stop sequences may have been playing a role (Falchieri, 2012), as had already been 
found to affect protection induced by candidate vaccines only differing in the their 
SH gene ends (Naylor et al., 2007).  Similarly in the current study it proved 
impossible to detect monocistronic SH mRNA in a German field strain which 
implies that the downstream G gene would be unlikely to be expressed, and may 
well help explain why in a previous study, the deletion of this G gene from the same 
virus only marginally reduced its protective capacity (Naylor et al., 2010).  
Nonetheless stop sequence differences between subtypes were not generally greater 
than those within subtypes, hence supported the notion of a subtype independent 
RG system. 
The above data taken as whole suggested that for an AMPV RG system subtype A 
and B components might be fully interchanged. This proved the case  because when 
subtype B components became available they proved able to be substituted for 
subtype A components in the RG systems – and once a fully subtype B RG had been 
produced, both subtype A and B full length genome copies were shown to efficiently 
produce virus when using either subtype A or B support proteins. This indicates that 
the viral polymerase of either subtype is able to attach to the leader and trailer, to 
recognise gene start and stop sequences, and that the key viral protein genes shared 
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sufficient functional similarity to support rescue. It remains uncertain as to whether 
subtype A/B components might be able to recover a full length subtype C copy, 
though this could easily be tested through collaboration between groups in 
possession of the different RG systems.  
As a more practical point, the cloning of genome copies in bacterial plasmids offer 
considerable flexibility when compared to alternatives more able to handle difficult 
sequences such as cloning into bacterial artificial chromosomes or other larger 
viruses such as fowlpox or vaccinia. In this study the previously recognised ability 
of pSMART to accept influenza virus genome segments has been extended to 
include the full genomes of an AMPV genome exhaustively proven very difficult to 
otherwise clone. It would interesting to know the limits of this approach and perhaps 
explore potential with larger viruses such as coronaviruses. 
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5. MAKING AND TESTING SUBTYPE B AVIAN 
METAPNEUMOVIRUS IBV RECOMBINANTS 
 
5.1 INTRODUCTION 
 
Infectious bronchitis virus (IBV) is a coronavirus, belonging to the family 
Coronaviridae, subfamily coronaviranae; it is a major pathogen of chickens and it 
is distributed worldwide. The primary tissue of replication of the virus is the 
respiratory tract, but it has shown the ability to infect also kidneys, intestine and 
reproductive system (Cook et al., 2012; Dhinakar Raj and Jones, 1997; Jackwood e 
de Wit, 2013). IBV has a positive sense non-segmented RNA genome, which can 
undergo recombination, thus leading to the emergence of new variants. New 
variants can have major disease significance if they are able to avoid protection 
induced by prevailing vaccines. (Capua et al., 1999; Cook et al., 1996b). The 
development of IBV-AMPV recombinant vaccines might help overcome those 
problems, because AMPVs field recombinants have never been demonstrated. 
Recombinant vaccines could also avoid the interference observed during co-
vaccination of one-day-old chickens with two or more live attenuated vaccines 
(Cook et al., 2001; Ganapathy et al., 2005; Ganapathy et al., 2006)  
Reverse genetics systems for avian matepneumovirus (AMPV) subtypes A and C 
have been developed (Naylor et al., 2004; Govinfarajan et al., 2006), allowing the 
generation of viruses with gene deletions,  mutations and reporter gene insertion 
(Brown et al., 2011; Govindarajan et al., 2006; Ling et al., 2008; Naylor et al., 2010). 
The similar tropism of this virus for the tissues of the respiratory tract, pointed to 
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AMPV as an ideal candidate vector for the expression of IBV immunogenic 
proteins. In 2013 the first AMPV-A/IBV recombinant viruses were generated 
(Falchieri et al., 2013). Birds vaccinated with the recombinant viruses were 
challenged with an homologous IBV strain and some protection was seen. The low 
level of protective immunity might be attributed to the poor replication of the 
recombinant viruses observed in the trachea of the vaccinated birds. In recent years 
subtype B has shown to be the most detected in chicken farms, and infection studies 
suggested that this subtype replicates better in chicken compare to the other 
subtypes (Aung et al., 2008). For this reason AMPV subtype B was supposed to 
have better potential to deliver foreign genes.  
Nuceocapsid (N) and the distal half of spike (S1) are believed to be the major 
immunogenic proteins of IBV: the N protein is able to stimulate a cell mediated 
immune response (Seo et alk., 1997), while the S1 gene is more more likely to 
stimulate the antibody production (Cavanagh et al., 1986: Mockett et al., 1984) In 
the present study, (N) and (S1) protein genes of IBV Massachusetts (Mass) were 
cloned into a plasmid containing the full length (FL) DNA genome copy of a 
commercial AMPV subtype B vaccine (RhinoCV-Intervet). The plasmids were 
transfected into VERO cells and the recombinant viruses were rescued. The 
recombinants generated were inoculated into specific pathogens free (SPF) chickens 
to determine their ability to induce protective immunity against a virulent IBV Mass 
strain. The protection was assessed by observation of the recovery of the cilial 
motility in the trachea of the challenged birds, as specified by the European 
Pharmacopoeia. Beyond the protective immunity, the ability of the recombinants to 
transcribe the exogenous genes, to replicate in vivo and to induce an immune 
response were also evaluated. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Addition of the cloning cassette 
An XhoI restriction endonuclease (RE) site was added by site directed mutagenesis 
(SDM) (see methods chapter (mc)3.7) into the G-L intergenic region of a plasmid 
containing the full length DNA copy of an AMPV subtype B based on RhinoCV 
(Intervet) sequence. The cloning cassette was made by annealing two 
complementary primers which include a transcriptional start (GGGACAAGT), a 
Sal I restriction endonuclease site (GTCGAC) and a transcriptional stop 
(AGTCAATAAAAAA). The cloning cassette was ligated into the XhoI site (mc 
3.6). This was transformed (mc 3.8) and the colonies were first checked by PCR 
(3.3) using primers matching on either side of the cassette site and by RE analyses 
of PCR products (mc3.9) before being grown in liquid culture (mc 3.8). The 
plasmids were extracted using Qiamp miniprep mini kit (Qiagen) and checked for 
integrity with RE (mc 3.9). PCR was performed across the G-L junction on 
apparently correct plasmids and the amplicons were sequenced (mc 3.5) to assess 
the orientation and the integrity of the cassette. 
 
5.2.2 IBV S1 and N genes amplification and insertion 
Infectious bronchitis virus (IBV) RNA was extracted from a Massachusetts (Mass) 
strain, using Qiamp viral RNA minikit (Qiagen), following the manufacturer’s 
recommendation (mc 3.1). S1 and N genes were reverse transcribed (mc 3.2) and 
the cDNAs amplified using primers introducing XhoI site at the extremities (mc 
3.3). The amplicons were ligated (mc 3.6) into the SalI site of the cassette. The 
plasmids obtained were transformed in competent cell (mc 3.8) and the colonies 
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were screened by PCR to check the correct orientation of the exogenous genes (mc 
3.3). The positive colonies were liquid cultured (mc 3.8), the plasmids extracted 
(mc 3.1) and checked for integrity with RE (mc 3.9). The inserts genes were both 
amplified by PCR (3.3) and the sequences analysed (mc 3.5). 
 
 
Figure 5.1 Schematic representation of the method used to insert the exogenous genes into subtype B DNA genome copy. The 
cloning casette was insert in the G-L intergenic region of the subtype B genome copy. The S1 and N genes were amplified by high 
fidelity RT-PCR, using RNA extracted from a Mass strain as template and the ligated into the casette. 
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Name Sequence (5’…3’) Function 
G-L XhoI + CCTTTCACATCTAAAATAAAGCAAAAAGAACTCGAGAG
AAGAAAGAAAGAAAGAAAGAAGAAGAACAGCACACAA
C 
XhoI site addition  
G-L XhoI neg GTTGTGTGCTGTTCTTCTTCTTTCTTTCTTTCTTTCTTCTC
TCGAGTTCTTTTTGCTTTATTTTAGATGTGAAAGG 
XhoI site addition  
Cassette + TCGACGGGACAAGTCGACAGTAATTAAAAAAG Cloning cassette 
Cassette neg TCGACTTTTTTAATTACTGTCGACTTGTCCCG Cloning cassette 
N all neg ACTAATGAGAATCACAATAATAAAAAGCACAG N reverse transcription 
N Xho start + AAGGGACAACTCGAGCATGGCAAGCGGTAAGGC N amplification XhoI site 
N Xho end neg CTTTTTTTCATAACTACTCGAGTCAAAGTTCATTCTCTCC N amplification XhoI site 
N end + GATGATGAACCAAGACCAAAG N Screening and mRNA 
Dta-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTA  mRNA reverse transcription 
Dtc-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTC  mRNA reverse transcription 
Dtg-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTG mRNA reverse transcription 
Adaptneg GCATCTCGAGGCTTGTGGCT mRNA amplification 
S1 end neg CATCTTTAACGAACCATCTGG S1 reverse transcription 
S1 Xho Start + GTGGTAAGTTACTGCTCGAGGATGTTGGTAACACCTCTT
TTAC 
S1 amplification XhoI site 
S1 Xho end neg AAGGGACAACTCGAGCATGGCAAGCGGTAAGGC S1 amplification XhoI site 
S1 end + GCTGTTAGTTATAATTATCTAG S1 Screening and mRNA 
S1 675 + GGATCACCTAGAGGCTTGTTAGC S1 Sequencing 
S1 765 neg CACGATAGACAATAAACTTCTGCTTAAC S1 Sequencing 
B 7.46 neg GGTATGGTCGTCCTATAATGCAAGATCC N and S1 screening 
GAB 4 + GCTGATTGAGTGGTGCTGTACTAG N, S1 and cassette sequencing 
B 7.40 neg GGAGTCAGGCAGATACACATTCACCG N, S1 and cassette sequencing 
G 7 + GAAAAGACATTCAGTACATAC mRNA amplification 
SHf TAGTTTTGATCTTCCTTGTTGC  In vivo replication assessment 
SHr GTAGTTGTGCTCAGCTCTGATA In vivo replication assessment 
MB-SH-r FAM-CGCGATCATTGTGACAGCCAGCTTCACGATCGCG-
Iowa Black FQ (Probe) 
In vivo replication assessment  
Table 5.1 List of the primers used in the study and their functions 
 
5.2.3 Recovery of recombinant viruses 
The plasmids containing the modified sequence were transfected on VERO cells 
following the methodology described in paragraph 4.6. In the presence of cytopathic 
effect (CPE), the virus rescue was further confirmed by RT-PCR of viral mRNA 
and the inserted gene was sequenced (mc 3.2; 3.3; 3.5). Rescued viruses were 
further passaged in Vero cells to produce a sufficient yield for protection studies. 
Viruses were titrated in 48 well plates containing Vero cell monolayers. CPE end 
points were observed and titres were calculated. 
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5.2.4 S1 and N genes transcription 
In order to evaluate the transcription of the exogenous genes, the RNA was extracted 
from the VERO cells (mc 3.1) and amplified by RT-PCR following the protocol 
previously described in paragraph 4.2.3, except that primers within the genes were 
S1 end+ and N end+ for S1 and N genes respectively. 
 
5.2.5 In vivo trial 
Fifty Specific Pathogens Free (SPF) chickens were divided in 5 groups and each 
group was housed in a biological isolators. At 1 day-of-age chickens of groups 1-4 
were vaccinated by eye drop, with 4 log10 TCID50 of BN G-L, BS1 G-L, vB  and a 
commercial available Mass vaccine respectively (Table 5.3). Birds of group 5 
remained unvaccinated. All the vaccinated birds and half of the unvaccinated birds 
were challenged 21 days post vaccination (d.p.v.) with a dose of 4 log10 TCID50 of 
a virulent Mass type strain. Half the birds of each group were humanely killed 5 
days post challenge (d.p.c.) and tracheas collected. At 6 d.p.c. the remaining birds 
were humanely killed and the tracheas were collected. 
 
5.2.6 Serology 
Chickens from all the groups were bled 18 days post vaccination (d.p.v.). The sera 
were tested by ELISA using a kit direct against AMPV subtype B antibodies 
(Biocheck).  
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5.2.7 Recombinants replication in vivo 
To assess the replication in vivo of the AMPV-B recombinants, tracheal swabs were 
collected from the birds 5 d.p.v. The RNA was extracted from the swabs (mc 3.1) 
and amplified by real time RT-PCR following the protocol developed by Cecchinato 
et al. (2013). All reactions were carried out on LightCycler 480 (Roche Diagnostic) 
using a Superscript III Platinum One-Step Quantitative RT-PCR kit (Life 
Technologies). Primers and probes used were listed in table 5.1. A positive control 
with known titre was added at each reaction. 
 
5.2.8 Determination of tracheal cilia activity 
On days 5 and 6 post challenge (d.p.c.) the tracheas of 5 birds of each group were 
collected. The tracheas were cut in 1mm transverse section and for each trachea,  3 
upper, 4 middle and 3 lower sections were observed using low power microscopy 
to determine activity of the cilia. 
 
5.3 RESULTS 
 
5.3.1 IBV recombinants AMPV-B construction  
The N and the S1 amplicons generated by RT-PCR were ligated into the cassette in 
two separate reactions. The constructs containing the N gene were identified as BN 
G-L, while the constructs containing the S1 gene were identified as BS1 G-L. Only one 
BN G-L construct had no mutations in the N gene sequence and showed the expected 
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restriction endonuclease (RE) profile. 5 correct plasmids containing the S1 gene 
were identified.  
  
5.3.2 Recovery of the recombinant viruses 
The recovery of both the viruses was confirmed by the presence of cytopathic effect 
(CPE) on the VERO cell monolayer at 5 day post infection (d.p.i.) on the second 
passage for both the recombinants. Only one of the BS1 G-L constructs was recovered. 
As further confirmation of the virus recovery, amplicons of the expected size were 
obtained by RT-PCR targeting the AMPV viral mRNA. After 3 passages on VERO 
cell the recombinant virus’s titres were sufficient for vaccination with 4 log10 dose 
per bird in 100ul eye drop (Table 5.2). The sequencing of the insert genes did not 
show any mutations. RT-PCR targeting the mRNA demonstrated that the 
recombinant viruses actively transcribed the exogenous genes.  
 
Clone IBV Mass insert gene Titre on VERO cells 
vB None 5.5 log10/ml 
BN N 5.3 log10/ml 
BS1 S1 5.3 log10/ml 
Table 5.2 Summary of the viruses rescued and their titre in vitro 
 
5.3.3 Serology 
Antibodies against AMPV were generally not detected in the birds vaccinated with 
the recombinant vaccines, although one bird vaccinated with BS1 G-L showed 
seroconversion. Poor antibody response was observed also in birds vaccinated only 
with vB: seroconversion was detected in only 3 birds (Table 5.3). 
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5.3.4 Recombinants replication in vivo 
While AMPV qRT-PCR on trachea swabs showed replication of the recombinant 
in most birds, the replication was negligible. A similar replication was observed for 
vB (Table 5.3).  
 
5.3.5 Tracheal motility following challenge 
At 5 day post challenge (d.p.c.), none of the birds vaccinated with the recombinant 
viruses showed cilial motility. On 6 d.p.c. recovery was observed in a few sections 
of the trachea from birds vaccinated with BN G.L and BS1 G-L (Table 5.3). Birds 
vaccinated with a commercially available Mass vaccine showed full protection. 
Unvaccinated/ challenged birds and birds vaccinated with the AMPV vector showed 
no cilial motility, while unvaccinated/unchallenged birds showed full motility 
(Table 5.3). 
 
Groups Real-Time (5 d.p.v.) Serology 
(18 d.p.v.) 
% TOC beating 
Positve  I.D. mean 5 d.p.c. 6 d.p.c. 
BN 10/10 1 0/10 0 6 
BS1 8/10 10 1/10 0 8 
vB 9/10 10 3/10 0 0 
Mass n.d. n.d. n.d. 100 100 
Unvacc/challenged 0/5 0 0/5 0 0 
Unvacc/unchallenged 0/5 0 0/5 100 100 
Table 5.3 Effects of vaccination with three subtype B recombinats on virus replication, antibody response to AMPV and % TOC 
beating after challenge with IBV. 
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5.4 DISCUSSION 
 
Recombinants of avian metapneumovirus (AMPV) subtype B were generated for 
the first time. The recombinants contained the N protein and the S1 protein of 
infectious bronchitis virus (IBV), which are believed to be the major immunogenic 
proteins of the virus. The recombinants showed to be stable after passage in vitro 
and to be able to transcribe the IBV exogenous genes. In vitro the recombinants 
reached titre comparable to those generally observed for VERO cells adapt AMPVs 
(Naylor and Jones, 1993). Virus titre is of great importance in vaccine developments 
because if sufficient titre per cell culture area cannot be achieved, the vaccine 
candidate will be rejected on technical cost and grounds. 
When inoculated in one-day-old SPF chickens subtype recombinants conferred 
negligible protection at the challenge against an homologous IBV strain. The 
recombinants replicated poorly in the respiratory tract of the birds, the primary 
replication site of both AMPV and IBV. Poor replication was also observed for the 
vector without any exogenous genes, suggesting that the insertion of foreign genes 
did not affect the virus viability. The poor replication in the upper respiratory tract 
is likely to have prevented the induction of protection against IBV.  Using the 
reverse genetics system it would be possible to verify this hypothesis modifying the 
sequence of the vector in order to increase the replication in vivo.   
No significant differences in term of protection, replication and antibody response 
were observed between the two recombinants.  In a previous study the subtype A 
recombinant expressing the QX N protein protected better than that expressing QX 
S1 (Falchieri et al., 2013). This difference was not seen using the current Mass 
recombinants. This might be due to the differences between QX and Mass proteins 
or differences between the challenge models. Alternatively the low level of 
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replication of the viruses may give insufficient inserted gene expression to provide 
stimulation of the immune response. Again, this could be tested by modifying the 
viruses by reverse genetics to increase their replication in vivo. 
Despite the low replication and the poor protection, AMPV-B remained a 
potentially promising vector. The subtype B virus was shown to be able to accept 
almost 2000 extra nucleotides without affecting virus viability and the upper limits 
have not been yet determined. Furthermore, AMPV recombinants was shown to be 
stable after in vitro passage. This contrasts with single strand positive sense viruses 
such as IBV where just few passages results in sequence mutations and 
recombination events (Cavanagh, 2007).   
To conclude, AMPV subtype B was shown to be a suitable vector for the expression 
of IBV immunogenic proteins, but, as the recombinants tested were able to induce 
negligible protection, further studies need to be done in order to generate efficient 
vaccine. 
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6. IMPROVING THE REPLICATION IN VIVO OF SUBTYPE B 
AVIAN METAPNEUMOVIRUS IBV RECOMBINANTS 
 
6.1 INTRODUCTION 
 
Previously reverse genetics (RG) systems for the subtype A and C (Govindarajan et 
al., 2006; Naylor et a., 2004) were made and more recently a similar system for 
subtype B has been developed (chapter 4).  
Using subtype A RG system, the ability of AMPV to accept and express exogenous 
genes has been demonstrated, thus identifying this virus as an ideal candidate vector 
for the expression of immunogenic proteins of other poultry respiratory viruses 
(Falchieri et al., 2013). Subtype A and B AMPV/IBV stable recombinants has been 
generated, but they all replicated poorly in vivo and conferred negligible protection 
at the challenge (Falchieri et al., 2013: chapter 5). A correlation between the poor 
replication and the negligible protection was suggested and it was hypothesised that 
increasing the recombinant’s replication in the trachea might improve the ability to 
induce protective immunity. 
The recombinant viruses developed in the previous chapter were based on the 
sequence of a commercial available vaccine (RhinoCV-Intervet). Another 
commercial available AMPV subtype B vaccine, Nemovac (Merial), was shown to 
replicate better in chicken (private communication). In the present study the full 
genome sequences of Nemovac and RhinoCV were compared and all the coding 
changes were identified. Most of the coding changes were corrected and a plasmid 
containing a hybrid AMPV subtype B FL genome sequence was generated. The 
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sequences of the S1 and N genes of a Massachusetts (Mass) IBV strain were cloned 
into the G-L intergenic region of the chimera FL cDNA.  
To further increase protection, another approach has also been followed. Several 
studies indicate that the co-expression of Interleukins can enhance the efficacy of 
live vaccine (Göbel et al., 2003; Winfried et al., 2004). Interleukin-18 (IL-18) plays 
an important role in the inflammatory reaction in chickens, stimulating the release 
of interferon ɣ (IFN-ɣ) (Schneider et al., 2000). Chicken’s IL-18 gene was amplified 
by PCR and cloned in a second cloning cassette added downstream the S1 or the N 
gene of the chimera FL cDNA.  
Plasmids generated were transfected into Vero cells. The rescued viruses were 
tested for the ability to induce protective immunity against challenge with a 
homologous IBV virulent strain. The ability of the recombinants to replicate in vivo 
and to transcribe and express the exogenous genes was also evaluated. 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Subtype B vaccines comparison 
RhinoCV and Nemovac RNA was extracted using Qiamp Viral RNA minikit 
(Qiagen) following the manufacturer’s recommendation (see methods chapter (mc) 
3.1). The RNA was reverse transcribed (mc 3.2) and amplified by PCR (mc 3.3). 
All the amplicons were purified and sequenced by Source Bioscience Sequencing 
(Cambridge UK) and the full genome sequences generated were analysed using 
Bioedit Sequence Alignment Editor. The primers used are listed in table 6.1. The 
full genome sequences of the virus were translated and analysed using Generunner. 
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6.2.2 Chimera AMPV-B construcion 
Nemovac RNA was extracted (mc 3.1), reverse transcribed (mc 3.2) and the cDNA 
was amplified (mc 3.3) to cover the region from the beginning of the F gene, to the 
end of the G gene. The amplicons were used as megaprimers in site directed 
mutagenesis (SDM) to convert the RhinoCV FL cDNA sequence (mc 3.7). Failures 
in both RT-PCR and SDM forced the adoption of a new approach. The sequence to 
be modified was further analysed and a region reach in G-C content was identified 
at the end of the G gene, suggesting a possible role in the poor amplification and 
genome modification performances. Thus the cDNA was amplified in two separated 
PCRs (mc 3.3): the first covered the F, M2, SH genes and the beginning of the G 
gene, the second one covered the rest of G gene, including the G-C reach region. 
An SDM was performed on the plasmid containing the RhinoCV sequence, using 
the first amplicon as megaprimer (m 3.7). The SDM products were transformed on 
STB12 cells, grown on liquid culture (mc 3.8) and plasmids were purified and 
checked for integrity by restriction endonuclease (RE) analysis (mc 3.9). The 
modified region was amplified and sequenced (mc 3.5). On plasmids showing the 
expected sequence a second SDM was performed, using the second PCR amplicons 
as megaprimer (mc 3.7). Firstly the modified region and then the full plasmids were 
sequenced and analysed (mc 3.5).  
 
6.2.3 IBV S1 and N genes amplification and insertion 
The N and the S1 genes were amplified and cloned into the chimera plasmid 
following the same protocol described in paragraph 5.2.2. Briefly, an XhoI site was 
introduced in the G-L intergenic region by SDM (mc 3.7) into which the cloning 
cassette was ligated (mc 3.6). The S1 or the N gene were then inserted into the 
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cloning cassette (mc 3.6). After each ligation step, the cloning site and the insert 
genes were sequenced (mc 3.5).  
 
 
 
Figure 6.1 Schematic representation of the method used to convert a RhinoCV DNA full genome copy. RhinoCV plasmid was 
modified by site directed mutagenesis in two steps by two high fidelity RT-PCR amplicons, generated using RNA extracted from 
Nemovac as template. 
 
6.2.4 Interleukin-18 (IL-18) gene amplification and insertion  
The Interleukin 18 (IL-18) was provided by Ceva Japan K.K. and it was amplified 
by PCR (mc 3.3) using primers introducing XhoI site at the extremities of the 
amplicons. SDM (mc 3.7), using primers containing a SalI site flanked by a 
transcriptional start and a transcriptional stop, was performed on the chimera 
plasmid containing the S1 gene sequence. The amplicons of IL-18 were ligated into 
the SalI site of the cloning cassette (mc 3.6). Plasmids containing the two exogenous 
genes were transformed on STB12 cells, liquid cultured (mc 3.8), purified and cut 
with RE (mc 3.9). Both the insert genes were amplified and sequenced (mc 3.5).  
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A different approach was used to generate the N+IL-18 chimera plasmid, as 
described in figure 6.2. Primers were designed to remove by PCR (mc 3.3) the S1 
gene from the plasmid containing the S1 and IL-18 genes. The linearized plasmid 
was ligated (mc 3.6) with the N gene amplicons and transformed on STB12 cell (mc 
3.8). Purified plasmids were screened by PCR (mc 3.3) and checked for integrity 
with RE (mc 3.9). The N and the IL-18 genes were amplified and sequenced (mc 
3.5). 
 
 
 
 
 
Figure 6.2 Schematic representation of the method used to insert the N gene in the construct containing the S1 and the IL-18 
genes. The S1 gene was removed by high fidelity PCR and the linearized PCR product was ligate with the N gene, previosly 
amplify by high fidelity RT-PCR, using RNA extracted from an IBV Mass strain. 
 
 
6.2.5 Recovery of recombinant viruses 
The plasmids generated (Table 6.4) were transfected into VERO cells following the 
procedure described in paragraph 4.6. The observation of cytopathic effect (CPE) 
was used as confirmation of the presence of the virus. As further confirmation, the 
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viral RNA was extracted (mc 3.1) from the cell sheets showing CPE and a RT-PCR 
(mc 3.2; 3.3) directed against AMPV viral mRNA was performed. The insert genes 
were sequenced in order to exclude any corruptions or mutations (mc 3.5). Rescued 
viruses were further passaged and titrated on VERO cells ready for protection 
studies. 
 
RT-Primers 
Name Sequence 
Ac le A tr 15 ACGAGAAAAAAACGC 
M2 Start + GATGTCTAGGCGAAATCCC 
L 2 + GAAAGGGAACTAAGTGTAGG 
L end B neg CTTTATGGTCTATTTTGTGCTCAGTATGTACC 
PCR primers1  
Name Sequence 
B.003 + ACAAGTCACAATAGAAAAGAGA 
NP 1.25 neg GACATTTTCACTTGTCCCGAATTTTTAATTACTC 
NAB 2 + CTAGATCCCTCAAAGAGAGCAACAAG 
B 2680 neg CTAGATCCCTCAAAGAGAGCAACAAG 
MAB 1 + GGACAACAACCCTGCAAAACTGAC 
FAB 4 neg CTCAACTGATGTAGCCCATGTTGC 
FAB 3 + CTAATGACTTACTGGACATAGAGGTTAAGAG 
G 3 NEG  ACTAGTACAGCACCACTC 
G 15 + B GCAAGACGACCGACCAGAGAC 
B 7840 neg CATCTCTGCAGCATTGGACATATCG 
LAB 1 + CTGGAAGTGTCACAGACCAGTGC 
LAB 4 neg CCCCACACTTAATTCCCTTTCTTTTCC 
LAB 3 + CGTGTACTAGAGTTTTACTTGAAGGATGC 
LAB 9 neg CAAGTTAATGTCCTCATTTCCAAATCTCTCAC 
LAB 8 + GTAGACCGATGGAGTTTCCTTCATCAG 
L end B neg CTTTATGGTCTATTTTGTGCTCAGTATGTACC 
Sequencing primers  
Name Sequence 
MAB 3 + GAGAGCTTAGGGAAAATATGCAAAACATGG 
FAB 1 + GCTAAAACAATAAGATTAGAAGGGGAGGTG 
FAB 2 + ATGACTATGTGTTCTGTGATACTGCAGC 
M2 AB 1 + GAATCCAGCAAATCTCATAAACAGTCTCAAG 
GAB 3 neg GTATCTCCCTGACAAATTGGTCCTG 
GAB 1 + GGCTTGACGCTCACTAGCACTATTG 
GAB 4 + GCTGATTGAGTGGTGCTGTACTAG 
B 7.40 neg GGAGTCAGGCAGATACACATTCACCG 
B 7.90 neg  ATTCCAACAGCTTTTACGGAGG 
LAB 2 + GATATGTCCAATGCTGCAGAGATG 
LAB 6 + GGAGACCCTGTTGTTGTGTATAGGAG 
LAB 7 + CATTGATAGAGCAGTTCATATGATGTTGCTC 
LAB 10 + CATTGATAGAGCAGTTCATATGATGTTGCTC 
1 All primers used to generate the PCR products, were also used for the full genome sequencing 
Tabella 6.1 List of the primers used to sequence the full AMPV subtype B genome 
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Name Sequence (5’…3’) Function 
FAB 1 + GCTAAAACAATAAGATTAGAAGGGGAGGTG Nemovac amplification 
GAB 3 neg GTATCTCCCTGACAAATTGGTCCTG Nemovac amplification 
G 16 + B CCTTACATCGAGGACAGTCAAC Nemovac amplification 
Nem 7090 neg GACTAGGATTGTAAGTTCCTACCTGG Nemovac amplification 
G-L XhoI + CCTTTCACATCTAAAATAAAGCAAAAAGAACTCGAGAG
AAGAAAGAAAGAAAGAAAGAAGAAGAACAGCACACAA
C 
XhoI site addition  
G-L XhoI neg GTTGTGTGCTGTTCTTCTTCTTTCTTTCTTTCTTTCTTCTC
TCGAGTTCTTTTTGCTTTATTTTAGATGTGAAAGG 
XhoI site addition  
Cassette + TCGACGGGACAAGTCGACAGTAATTAAAAAAG S1 and N cloning cassette 
Cassette neg TCGACTTTTTTAATTACTGTCGACTTGTCCCG S1 and N cloning cassette 
N all neg ACTAATGAGAATCACAATAATAAAAAGCACAG N reverse transcription 
N Xho start + AAGGGACAACTCGAGCATGGCAAGCGGTAAGGC N amplification XhoI site 
N Xho end neg CTTTTTTTCATAACTACTCGAGTCAAAGTTCATTCTCTCC N amplification XhoI site 
N end + GATGATGAACCAAGACCAAAG N Screening and mRNA 
S1 end neg CATCTTTAACGAACCATCTGG S1 reverse transcription 
S1 Xho Start + GTGGTAAGTTACTGCTCGAGGATGTTGGTAACACCTCTT
TTAC 
S1 amplification XhoI site 
S1 Xho end neg AAGGGACAACTCGAGCATGGCAAGCGGTAAGGC S1 amplification XhoI site 
S1 end + GCTGTTAGTTATAATTATCTAG S1 Screening and mRNA 
S1 675 + GGATCACCTAGAGGCTTGTTAGC S1 Sequencing 
S1 765 neg CACGATAGACAATAAACTTCTGCTTAAC S1 Sequencing 
S1 ins + CACTAATGGAACATAGTTATTAAAACGTTAACGGGACA
AGTCGAC 
IL-18 cloning cassette 
S1 ins - CGGATATTTCCATACTTGTCCCTGTTTTTCTCGACTTTTT
GTCGA 
IL-18 cloning cassette 
IL-18 Xho + CTTCCAGAGATTGGCTCGAGGATGAGCTGTG IL-18 amplification XhoI site 
IL-18 Xho neg GTTCGAGGATTCTCGAGATATATCATAGGTTG IL-18 amplification XhoI site 
IL-18 285 + GCCTGTTGCATTCAGCGTCC IL-18 screening and mRNA 
IL-18 345 neg CGAACAACCATTTTCCCATGCTC IL-18 sequencing 
S1 rem Sal + GTTTTACATTGTCGACACTAATGGAACATAGTTATTAAA
CG 
S1 removal 
S1 rem Sal neg GTTACCAACATCGTCGACTTCTTGTCCCTTTCTTCTTTTT
GC 
S1 removal 
B 7.46 neg GGTATGGTCGTCCTATAATGCAAGATCC Insert genes screening 
GAB 4 + GCTGATTGAGTGGTGCTGTACTAG Insert genes sequencing 
B 7.40 neg GGAGTCAGGCAGATACACATTCACCG Insert genes sequencing 
Dta-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTA  mRNA reverse transcription 
Dtc-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTC  mRNA reverse transcription 
Dtg-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTG mRNA reverse transcription 
Adaptneg GCATCTCGAGGCTTGTGGCT mRNA amplification 
G 7 + GAAAAGACATTCAGTACATAC mRNA amplification 
SHf TAGTTTTGATCTTCCTTGTTGC  In vivo replication assessment 
SHr GTAGTTGTGCTCAGCTCTGATA In vivo replication assessment 
MB-SH-r FAM-CGCGATCATTGTGACAGCCAGCTTCACGATCGCG-
Iowa Black FQ (Probe) 
In vivo replication assessment  
Table 6.2 List of the other primers used in the study and their functions 
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6.2.6 Exogenous genes transcription 
The ability of the rescued viruses to transcribe the exogenous genes was evaluated 
by RT-PCR (mc 3.2; 3.3). The RNA was extracted from the VERO cell (mc 3.1). 
The protocol described in paragraph 4.2.3 was adopted, except that primers within 
those genes were S1 end+, N end+ and IL-18 285+for S1, N and IL-18 genes 
respectively. 
 
6.2.7 Exogenous proteins expression 
S1 and N protein expression was assessed using immunofluorescence (IF) on 
AMPV recombinant infected VERO monolayers. A polyclonal chicken antiserum 
(GD) anti Mass was used to evaluate S1 expression and a monoclonal mouse 
antibody (Biozol) was used to evaluate the N expression. Suitable FITC conjugated 
anti chicken/mouse antibodies (Sigma) were used according to manufacturers’ 
protocols to enable visualization of specific S1/N proteins. 
 
6.2.8 Sequences comparison of two cBN G-L plasmids 
Mapping PCR was performed on two plasmids containing the N gene (cBN G-L). 
One, lab code 629, was successfully rescued, while the other, lab code 627, wasn’t 
rescued. The amplicons generated were sequenced and aligned (mc 3.5). The full 
genome sequences obtained were compared and analysed (mc 3.5). 
 
 
 
72 
 
6.2.9 In vivo trial 
Seventy Specific Pathogens Free (SPF) chickens were divided in 7 groups and each 
group was housed in biological isolators. At 1 day of age chickens of groups 1-5 
were vaccinated by eye drop, with 4 log10 TCID50 of cBN G-L, cBS1 G-L, cBS1+IL-18 G-
L, cvB  and a commercially available Mass type vaccine respectively (Table 6.5). 
Group 6 were vaccinated with a higher dose of cBN G-L (5 log10 TCID50). Birds of 
group 7 remained unvaccinated. All the vaccinated birds and half of the 
unvaccinated birds were challenged 21 days post vaccination (d.p.v.) with a dose of 
4 log10 TCID50 of a virulent Mass type strain. Half the birds of each group were 
humanely killed 5 days post challenge (d.p.c.) and the tracheas were collected. On 
6 d.p.c. the remaining birds were humanely killed and the tracheas were collected. 
 
6.2.10 Recombinants replication in vivo 
The replication in vivo of the AMPV-B chimeras were assessed by real time RT-
PCR following the protocol developed by Cecchinato et al. (2013). Tracheal swabs 
were collected from the birds 5 d.p.v.. The RNA was extracted from the swabs using 
Qiamp viral RNA mini kit (Qiagen): all reactions were carried out on a LightCycler 
480 (Roche Diagnostic) using a Superscript III Platinum One-Step Quantitative RT-
PCR kit (Life Technologies). Primers and probes used were listed in table 6.2. A 
positive control with known titre was added at each reaction. 
 
6.2.11 Determination of tracheal cilia activity 
On days 5 and 6 post challenge (d.p.c.) the tracheas of 5 birds of each group were 
collected. The tracheas were cut in 1mm transverse section and for each trachea, 3 
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upper, 4 middle and 3 lower sections were viewed using low power microscopy to 
determine activity of the cilia. 
 
6.3 RESULTS 
 
6.3.1 Subtype B vaccines comparison 
Eight amplicons of the expected size were generated by RT-PCR both for RhinoCV 
and Nemovac. The comparison of the sequences revealed the presence of 133 
nucleotide changes between the two viruses, of which 41 were coding (Table 6.3). 
The majority of the coding changes (27) were observed in the F, SH, M2 and G 
genes, with G showing the lowest similarity 13 coding changes.  
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Figure 6.3  Nucleotide and aminoacid alignment of Nemovac and RhinoCV. 
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6.3.2 Chimera AMPV-B construction 
Two amplicons covering the F, M2, SH and G genes were generated and then used 
in two consecutive SDM steps. After the two SDM steps, only one plasmid showed 
the correct RE pattern. The sequence analysis of the plasmid confirmed that the F, 
M2, SH, and G gene were fully converted to Nemovac sequence. The plasmid was 
named cvB (chimera vector subtype B). 
 
6.3.3 Exogenous genes addition 
The cloning cassette was added at the G-L intergenic region. The N and the S1 
amplicons obtained by RT-PCR were cloned into the cassette in two separate 
reactions. Four FL plasmids containing the N gene were positive both by PCR and 
RE screening, while 3 plasmids were positive for the S1 gene insertion. The 
sequence analysis of the inserted genes did not show any mutations. Interleukin-18 
was amplified by PCR and then cloned. Three plasmids containing the N and the 
IL-18 genes and 5 plasmids containing the S1 and the IL-18 genes were generated. 
Sequencing analyses confirmed that no mutations were present in any of the 
exogenous genes. 
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  Nucleotide changes Amino acid chamges 
Gene Position Nemovac RhinoCV Nemovac RhinoCV 
N 
375 A G Glutamine Arginine 
905 A G Lysine Glutamic acid 
M 
2603 C T Histidine Tyrosine 
2768 A G Serine Glycine 
F 
3481 A C Leucine Asparagine 
3705 G A Arginine Leucine 
3914 A G Lysine Glutamic acid 
4443 C T Alanine Valine 
4511 T C Serine Proline 
M2:1 
5136 G A Glycine Aspartic acid 
5141 G A Glycine Serine 
M2:2 
5136 G A Valine Methionine 
5152 G A Serine Lysine 
5164 T C Leucine Serine 
SH 
5383 G A Glutamic acid Lysine 
5640 G C Glutamin Histidine 
5644 C T Histidine Tyrosine 
5699 A G Asparagine Glutamic acid 
G 
6375 G A Arginine Histidine 
6468 A G Aspartic acid Glycine 
6529 C A Asparagine Lysine 
6651 G A Glycine Glutamic acid 
6680 A G Serine Glycine 
6749 C A Glutamine Lysine 
6764 G A Glycine Serine 
6795 G A Serine Aspartic acid 
6864 G A Glycine Glutamic acid 
7006 T A Aspartic acid Lysine 
7029/7030 TT CC Leucine Proline 
7065 A C Glutamine Proline 
7151 C T Histidine Tyrosine 
L 
7548 G  A Glycine Serine 
7833 G A Valine Isoleucine 
8298 T C Tyrosine Histidine 
8447 A T Leucine Phenylalanine 
8640 G A Glycine Serine 
11367 A G Methionine Valine 
11766 A G Serine Glycine 
11787 G A Aspartic acid Asparagine 
11953 A G Glutamic acid Glycine 
13143 G A Glycine Serine 
Table 6.3 List of the coding changes detected after comparison of nucleotide and aminocid sequence of Nemovac and RhinoCV. 
The highlighted changes were modified by SDM. 
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6.3.4 Recovery of recombinant viruses 
Not all the plasmids transfected into Vero cells were recovered. The  presence of 
cytopathic effect (CPE) on the Vero cell monolayers was observed for cvB, for one 
of the cBS1 G-L constructs, for one of the cBN G-L constructs and for one of the cBS1+IL-
18 G-L constructs. No CPE was observed in any of the cell sheets transfected with 
construct cBN+IL-18 G-L. RT-PCR targeting the AMPV viral mRNA detected the viral 
mRNA only in monolayers showing CPE. After 3 passages on Vero cells, all the 
recombinant viruses reached a titre sufficient for a protection study. Different titres 
were obtained for the recombinants; the highest titre was observed for cBN G-L virus, 
reaching 6.5 log/ml. The sequencing of the insert genes showed gene sequences to 
be correct. 
 
Clone name Insert gene No. Plasmids No. Rescued Titre 
cvB none 1 1 5.5 log10/ml 
cBN G-L N 4 1 6.5 log10/ml 
cBS1 G-L S1 3 1 5.6 log10/ml 
cBN+IL-18 G-L N and IL-18 3 None n.d. 
cBS1+IL-18 G-L S1 and IL-18 5 1 5.5 log10/ml 
Tabella 6.4 Summary of the constructed recombinant cloned FL cDNAs, of the recombinant viruses rescued and their 
titre on VERO cell 
 
6.3.5 Sequences comparison of two cBN G-L plasmids 
The full genome sequences of two plasmids containing the N gene (cBN G-L) were 
analysed. No nucleotide changes were observed between plasmid 629, successfully 
rescued, and plasmid 627, not rescued. 
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6.3.6 Exogenous genes transcription and expression 
RT-PCR targeting the mRNA demonstrated that the recombinant viruses actively 
transcribed the exogenous genes. Immunofluorescence confirmed that the 
exogenous proteins were expressed by all the recombinants (see pictures 6.4). 
 
 
Figure 6.4 Microscopy of VERO cells infected with 3 AMPV-B/IBV recombinants and negative control. A: 
immunofluorescence using FITCH specific antibodies. B: white light illumination. Viruses 1 to 4 used IBV polyclonal 
chicken serum, viruses 5 to 7 used N monoclonal serum.  
 
6.3.7 Recombinants replication in vivo 
All the recombinants tested replicated in the trachea of the birds. The recombinant 
showing the higher replication was the cBS1 G-L. Construct cBN G-L replicated better 
when administered to the birds at the lower dose (Table 6.5). 
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6.3.8 Tracheal motility following challenge 
On 5 and 6 days post challenge (d.p.c.), recovery of the cilial beating was observed 
in all the groups vaccinated with the recombinants. The protection varied among the 
different recombinants and cBN G-L group showed the best protection (Table 6.5). 
Stronger cilial recovery was observed in the birds vaccinated with cBS1+IL-18 G-L 
compared to cBS1 G-L (Table 6.5). Nevertheless, none of the recombinants showed 
the cilial recovery required by the European Pharmacopoeia.  
Birds vaccinated with the commercially available Mass vaccine showed full 
protection. Unvaccinated/challenged birds showed no cilial motility, while 
unvaccinated/unchallenged birds showed full motility (Table 6.5). Low recovery 
was observed also in birds vaccinated with cvB (Table 6.5). 
 
Groups Real time  (5 d.p.v.) %TOC 
beating 
50% beating 
rings  Positive I.D. (mean) 
cvB 8/10 1000 20% 2% 
cBN G-L (low dose) 6/10 100 86% 14% 
cBN G-L (high dose) 10/10 1000 70% 13% 
cBS1 G-L 10/10 1000 42% 5% 
cBS1+IL-18 G-L 7/10 100 48% 5% 
Mass n.d. n.d. 100% 100 
Unvacc/challenged 0/5 0 0% 0% 
Unvacc/unchallenged 0/5 0 100% 100 
Tabella 6.5 Effects of vaccination with three subtype B recombinants on virus replication, antibody response to 
AMPV and % TOC beating after challenge with IBV. 
 
6.4 DISCUSSION 
 
The comparison of the full genome sequence of RhinoCV (Intervet) and Nemovac 
(Merial) revealed that most coding changes (27) were located in the genes coding 
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for the proteins involved in the fusion and release of the virions from the host cell 
surface (Fusion (F), Small Hydrophobic (SH) and the Attachment (G) proteins). A 
plasmid characterized by a hybrid sequence of RhinoCV (N, P, M and L genes) and 
Nemovac (F, M2, SH and G genes) was generated and rescued. A comparison of 
the viral titres detected in the trachea of birds vaccinated respectively with the 
chimera virus and with RhinoCV revealed that the chimera titres was 100 times 
higher, suggesting that the chimera virus has a better potential to deliver foreign 
genes.  
AMPV-B/IBV stable recombinants based on the hybrid sequence were generated, 
inoculated into SPF chickens and challenged against a virulent Mass IBV strain: 
cilial recovery was observed in all the groups. The cilial recovery was markedly 
higher than that observed in chapter 5 for RhinoCV recombinants and the 
comparison of the virus titres detected in the trachea of the birds revealed that the 
chimera recombinants reached titres 1000 times higher than the previous subtype B 
recombinants. These data confirm that high replication in the respiratory tract 
doesn’t imply the induction of protective immunity. Nevertheless the 
pharmacopoeia requirements were not matched. It’s possible that despite the high 
replication, the expression of the exogenous genes wasn’t enough to stimulate a 
strong immune response in the host. The transcription mechanism of AMPV 
involves a gradually decrease in the mRNA production moving from the 3’ end to 
the 5’ end (Dimmock et al., 2007): inserting the exogenous gene into an intergenic 
region closer to the leader will increase the exogenous protein expression. 
Nevertheless, the site of insertion must be chosen very carefully, as in the previous 
study on subtype A recombinants indicated that the insertion of an exogenous gene 
too close to the 3’ end affected the virus viability (Falchieri et al., 2013). 
Differences in term of protection between the constructs were observed, with the 
highest cilial recovery detected in the birds vaccinated with the recombinants 
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expressing the N protein, in accordance with a study carried on using subtype A 
recombinants (Falchieri et al., 2013) but in contrast to a previous study conducted 
using subtype B recombinants (chapter 5), where no difference in terms of induction 
of protection was observed. To explain these contrasting results, it was previously 
supposed that that the low level of replication of the previous subtype B 
recombinants might have prevent a sufficient IBV proteins expression to stimulate 
the immune response in the host and the data obtained in the present study seems to 
confirm this hypothesis.   
For the first time a subtype B recombinant expressing more than one exogenous 
gene was rescued. A major cilial recovery was observed for the birds vaccinated 
with recombinant expressing both S1 and IL-18, when compare to those vaccinated 
with recombinant expressing only the S1 protein, confirming that the co-expression 
of IL-18 enhances the vaccine efficacy. The recovery of virus expressing N and IL-
18 proved to be impossible. The presence of these two exogenous genes placed in 
the same intergenic region might have prevented the transcription of the 
downstream gene, probably as a result of an interaction between the two exogenous 
sequences that led to the formation of RNA secondary structures.  It would be 
interesting to move the N gene to another intergenic region and then attempt the 
rescue of the virus containing both genes. Considering that the N protein proved 
able to induce better protection than the S1 and that IL-18 confirmed its ability to 
enhance vaccine efficacy, it’s likely that a recombinant expressing N and IL-18 
proteins might represent a step ahead in the development of effective AMPV-B/IBV 
recombinant vaccines. Despite the conflicting data, the ability of subtype B to accept 
and express two foreign genes could also be used to produce recombinants 
expressing both N and S1. In the study on subtype A recombinants, those expressing 
the two IBV proteins conferred the best protection (Falchieri et al., 2013). 
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For each construct, several plasmids were obtained, confirming that subtype B could 
be readily manipulated and suggesting that it would be possible to generate a large 
range of viruses for testing as candidate vaccines in protection studies. Nevertheless 
only a few viruses were rescued. In a previous study investigating AMPV adaptation 
on Vero cells it was shown that a single non conservative mutation in the M2:2 
protein could prevent the virus being rescued (Clubbe et al., 2011). It was therefore 
it was supposed that the low successful rate could be due to mutations introduced 
into the AMPV genome during one of the steps of the development of the plasmids. 
The comparison of the full genome sequence of two plasmids of construct cBN G-L, 
one rescued and one not rescued, did not show any nucleotide changes between 
them, seemingly disproving the mutations theory. This suggests that virus recovery 
is not totally reliable and that small changes in conditions to the reverse genetics 
system might have a large effect on outcomes.  
The chimera recombinant expressing the N gene showed an unexpected behaviour 
in vitro in reaching titres higher than any other recombinants and even higher than 
virus rescued from the unmodified vector. It may be possible that the IBV N gene 
enhanced the replication in vitro, even if a similar behaviour had not been observed 
in either the previous study on subtype B recombinants, nor in the subtype A study 
(Falchieri et al., 2013). If confirmed, the ability of the N gene to enhance the 
replication in vitro could be very useful at the production stage of the vaccine, as if 
sufficient titre per cell culture cannot be achieved, promising vaccines could be 
otherwise rejected due to required inoculation doses being unattainable. 
A group of birds was vaccinated with a 10 times higher dose of recombinant 
expressing the N protein. When compared to birds vaccinated with the usual dose,  
both the level of replication in the trachea and induced protection were reduced. 
Counterintuitively, the data might indicate that the vaccine dose is crucial for 
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efficient vaccination and that a higher viral dose might negatively affect the 
replication, and lead to a reduction in protection. 
In conclusion, while the chimera recombinants did not confer full protection, higher 
replication in the trachea and increased cilial recovery indicate that a step forward 
has been made in the development of effective recombinant AMPV-B/IBV 
vaccines. The recombinants confirm their ability to be actively transcribed and 
express exogenous genes. Furthermore the N protein has been confirmed as the 
major antigenic protein of IBV, IL-18 confirmed its ability to enhance the 
effectiveness of vaccines, subtype B was shown able to incorporate more than one 
exogenous gene and the failure in the recovery of virus expressing N and IL-18 
proteins suggested that the cloning of two foreign genes in the same intergenic 
region might affect the virus viability. As future developments, the generation of 
subtype B constructs containing IBV and IL-18 genes at two different intergenic 
region, as well as constructs containing both S1 and N, would be of interest. 
 
 
 
 
 
 
 
 
 
94 
 
7. INVESTIGATING THE ABILITY OF SUBTYPE B AVIAN 
METAPNEUMOVIRUS TO ACCEPT EXOGENOUS GENES AT 
MULTIPLE INTERGENIC POSITIONS 
 
7.1 INTRODUCTION 
 
In the two previous chapters, the development of two sets of avian 
metapneumovirus (AMPV) subtype B recombinant vaccines expressing infectious 
bronchitis virus (IBV) immunogenic proteins was described. None were able to 
induce enough protection at challenge to meet the pharmacopoeia requirements. The 
first set of recombinants used RhinoCV (Intervet) vaccine as vector to express N or 
S1 protein of IBV. Protection induced by the recombinants was challenge in vivo 
using an IBV homologous strain. The replication was poor replication in the trachea 
of the birds and little conferred protection. To increase the protection, a chimera 
vector with a hybrid RhinoCV/Nemovac (Merial) sequence was generated. Chimera 
recombinant viruses replicated to high titres in the trachea of the birds, but did not 
confer full protection at the challenge. It was supposed that the partial protection 
might be due to poor expression of exogenous proteins and that increasing the 
exogenous protein expression will improve the protection. 
 Using the subtype A RG system, Falchieri et al. (2013) introduced a reporter gene 
at each AMPV intergenic region and observed a decrease in the expression of the 
exogenous protein moving from the leader to the trailer. The maximum exogenous 
protein expression was observed at the N-P junction. These data are in accordance 
with a transcription mechanism for AMPV resulting from the viral polymerase only 
joining the genome at the viral leader and the polymerase being able to detach from 
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the genome at any stage before the trailer is reached (Dimmock et al., 2007). The 
same study revealed that the viability of the virus could be influence by the position 
of the reporter gene. High virus titres were obtained only when the insert gene was 
placed at the M-F junction or at downstream junctions, suggesting that in subtype 
A the M-F junction represent the best compromise between exogenous gene 
expression and virus viability (Falchieri et al., 2013). In the present study it was 
assumed that the same applies to subtype B. The N gene of a Massachusetts (Mass) 
IBV strain was therefore cloned into the M-F junction of the chimera plasmid.  
For subtype A, AMPV-A\IBV recombinants recombinant containing both the N and 
the S1 genes achieved the best protection after challenged with homologous 
IBV(Falchieri et al., 2013). IBV N protein is reported to stimulate a cell mediate 
immune response (CMI) (Seo et al., 1997) whereas the S1 protein is reported to 
stimulate antibody production (Cavanagh et a., 1986: Mockett et al., 1984). In the 
present study the N gene was cloned at the M-F intergenic region of two chimera 
plasmids containing respectively the solely S1 gene or both the S1 and the IL-18 
genes at the G-L junction.  
The Matrix (M) protein is one of the structural and surface proteins of IBV. To date 
there were no study showing this to be an immunogenic protein, but nevertheless its 
position on the viral surface suggest that the M protein should be further 
investigated. To study the role played by this protein and to potentially increase the 
ability of the recombinants to confer protective immunity, the M gene sequence was 
cloned into the G-L intergenic region of the chimera plasmid containing also the N 
gene; and in the M-F intergenic region of the chimera plasmid containing the S1 
and the IL-18 genes. 
All the constructs were transfected into Vero cells. Several virus rescue attempts 
were performed.  
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7.2 MATERIALS AND METHODS 
 
7.2.1 Plasmids preparation 
 
7.2.1.1 N gene cloning in the M-F intergenic region of the chimera vector (cvB). 
An XhoI restriction endonuclease (RE) site was added by site directed mutagenesis 
(SDM) (see methods chapter (mc) 3.7) into the M–F intergenic region of a plasmid 
containing an avian metapneumovirus subtype B chimera genome copy, based on 
RhinoCV (Intervet) and Nemovac (Merial) vaccines. As described in paragraph 
5.2.1, the cloning cassette contained a complimentary DNA copy of a 
transcriptional start (GGGACAAGT), a Sal I restriction endonuclease site 
(GTCGAC) and a complimentary DNA copy of a transcriptional stop 
(AGTCAATAAAAAA). The cassette was ligated (mc 3.6) into the XhoI site, the 
plasmids transformed and liquid cultured (mc 3.8), purified (mc 3.1), and screened 
by PCR (mc 3.3) and RE (mc 3.9). Correct plasmids were selected by sequencing 
(mc 3.5) of the cassette.  
Infectious bronchitis virus (IBV) RNA was extracted from a Massachusetts (Mass) 
field strain using Qiamp Viral RNA minikit (mc 3.1) and reverse transcribed (mc 
3.2). The cDNA was amplified (m 3.3) using primers introducing an XhoI site at 
the sequence ends. The amplicons were ligated (mc 3.6) into the cassette. The 
plasmid were transformed on STB12 cells (mc 3.8), screened by PCR (mc 3.3) to 
check for the correct orientation of the N gene, liquid cultured (mc 3.8), purified 
(mc 3.1) and checked for integrity by RE (mc 3.9). The insert gene was amplified 
(mc 3.3) and the sequences generated analysed (mc 3.5). 
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7.2.1.2 N gene cloning in the M-F intergenic region of plasmids containing the 
S1 and IL-18 genes in the G-L intergenic region (cBS1+IL-18 G-L) 
A high fidelity PCR (mc 3.3), using primers matching either side of the cassette, 
was performed on the plasmid containing the cassette in the M-F intergenic region. 
The amplicons generated were used as megaprimers in an SDM (mc 3.7) having as 
template plasmids containing the S1 and the IL-18 genes (cBS1+IL-18 G-L) in the G-L 
intergenic region. The N gene was ligated (mc 3.6) in the cassette, the plasmids 
transformed (mc 3.8), screened by PCR (mc 3.3), liquid cultured (mc 3.8) and 
checked for integrity with RE digestion (mc 3.9). Finally the N gene was amplified 
(mc 3.3) and sequenced (mc 3.5). 
 
7.2.1.3 M gene cloning in the M-F integenic region of plasmids containing the 
S1 and IL-18 (cBS1+IL-18 G-L) genes in the G-L intergenic region 
IBV RNA was extracted (mc 3.1) from a Mass field strain and reverse transcribed 
(mc 3.2). The cDNA was amplified (mc 3.3) using primers introducing XhoI site at 
the extremity of the M gene. The product generated was ligated (mc 3.6) into the 
cloning cassette at the M-F junction of the chimera plasmid also containing the S1 
and IL-18 genes in the G-L intergenic region (cBS1+IL-18 G-L).  After transformation 
(mc 3.8), the plasmid was screened by PCR (mc 3.3), liquid cultured (mc 3.8), 
purified (mc 3.1) and cut with RE (mc 3.9). The M genes of positive clones was 
amplified and sequenced. 
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7.2.1.4 M gene cloning in the G-L intergenic region of plasmids containing the 
N gene in the M-F intergenic region 
A high fidelity PCR (mc 3.3), using primers matching either side of the cassette, 
was performed on the plasmid containing the cassette in the G-L intergenic region. 
The amplicons generated were used as SDM megraprimers to introduce the cassette 
at the G-L junction of the plasmid containing the N gene in the M-F intergenic 
region. The M gene was ligated (mc 3.6) into the cassette at the G-L junction, the 
plasmids transformed (mc 3.8), screened by PCR (mc 3.3), liquid cultured (mc 3.8), 
purified (mc 3.1) and cut with RE (mc 3.9). The M gene was amplified (mc 3.3) and 
sequenced (mc 3.5). 
 
7.2.1.5 S1 gene cloning in the G-L intergenic region of plasmids containing the 
N gene in the M-F intergenic region 
The S1 gene inserted in plasmid cBS1 G-L was amplified using high fidelity PCR (mc 
3.3). The amplicons generated were used as megaprimers in an SDM, having as 
template the plasmid containing the N gene at M-F junction. The SDM products 
were transformed (mc 3.8), screened by PCR (mc 3.3), liquid cultured (mc 3.8) and 
checked for integrity by RE digestion (mc 3.9). The S1 gene was amplified (mc 3.3) 
and sequenced (mc 3.5). 
 
7.2.2 Recovery of recombinant viruses 
The plasmids containing the modified sequence were transfected on Vero cells in 
the presence of subtype B support genes, following the protocol described in 
paragraph 4.6. The cell sheets were daily examined for the presence of cytopathic 
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effect (CPE) typical of AMPV. After 6 days post infection (d.p.i.) the cell sheets 
were freeze-thawed and the material was used to infected new cell sheets. The new 
infected cell sheets were viewed daily for the presence of CPE up to 49 d.p.i. and a 
third passage was performed. Eventually, to check the presence of rescued viruses, 
RNA was extracted (mc 3.1) from the Vero cell monolayers of the third passages, 
reverse transcribed (mc 3.2) and amplified by PCR (mc 3.3). 
 
 
Name Sequence (5’…3’) Function 
Cassette + TCGACGGGACAAGTCGACAGTAATTAAAAAAG Cloning cassette  
Cassette neg TCGACTTTTTTAATTACTGTCGACTTGTCCCG Cloning cassette 
M-F Xho + GTCCACTATTCTGTAGTTTAATAAAAACTCGAGGGGGCA
AGTAAAATGTACCTCAAACTGCTAC 
Introduction XhoI site at M-F 
M-F Xho neg GTAGCAGTTTGAGGTACATTTTACTTGCCCCCTCGAGTTT
TTATTAAACTACAGAAGAATAGTGGAC 
Introduction XhoI site at M-F 
B 2.87 + CCAGAGAACTAGGTATGTCC Cassette at M-F amplification 
B 3.23 neg CCTATGGGAAAGGATTCGATTC Cassette at M-F amplification 
G13+B CAATCCTAGTCAATCGGGAACC Cassette at G-L amplification 
B 7.46 neg GGTATGGTCGTCCTATAATGCAAGATCC Cassette at G-L amplification 
RT 26.24 neg CCAAGATACATTTCCAG M reverse transcription 
M IBV Xho + TCCAGCAAATCTCGAGGATGTCCAACGAGACAAATTGTA M amplification Xho I site 
M IBV Xho neg TCTCTACACACTCGAGTTTATGTGTAAAGGCTACTTCCAC
TTG 
M amplification Xho I site 
IB 25.27 + GACGTAATATCTATCGTATGGTGCAG M screening  
N all neg ACTAATGAGAATCACAATAATAAAAAGCACAG N reverse transcription 
N Xho start + AAGGGACAACTCGAGCATGGCAAGCGGTAAGGC N amplification XhoI site 
N Xho end neg CTTTTTTTCATAACTACTCGAGTCAAAGTTCATTCTCTCC N amplification XhoI site 
N end + GATGATGAACCAAGACCAAAG N Screening  
GAB 1 + GGCTTGACGCTCACTAGCACTATTG S1 at G-L amplification 
B 7840 neg CATCTCTGCAGCATTGGACATATCG S1 at G-L amplification 
S1 end + GCTGTTAGTTATAATTATCTAG S1 Screening  
S1 675 + GGATCACCTAGAGGCTTGTTAGC S1 Sequencing 
S1 765 neg CACGATAGACAATAAACTTCTGCTTAAC S1 Sequencing 
MAB 3+ GAGAGCTTAGGGAAAATATGCAAAACATGG Insert genes sequencing 
FAB 4 neg CTCAACTGATGTAGCCCATGTTGC Insert genes sequencing 
GAB 4 + GCTGATTGAGTGGTGCTGTACTAG Insert genes sequencing  
B 7.40 neg GGAGTCAGGCAGATACACATTCACCG Insert genes sequencing  
Dta-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTA  mRNA reverse transcription 
Dtc-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTC  mRNA reverse transcription 
Dtg-Adaptneg GCATCTCGAGGCTTGTGGCTTTTTTTTTTTTTTTTTTTTTG mRNA reverse transcription 
Adaptneg GCATCTCGAGGCTTGTGGCT mRNA amplification 
Table 7.1 List of the primers used in the present study. 
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7.3 RESULTS 
 
7.3.1 Genes addition 
The cloning cassette was added at the M-F intergenic region of cvB plasmid and the 
N gene amplicons was ligated into it. Using PCR and restriction endonuclease (RE) 
digestion, one FL plasmid containing the N gene was found. And was named cBN 
M-F.  
The cloning cassette was also ligated at the M-F junction of plasmid cBS1+IL-18 G-L 
and the N and M genes were ligated into it in two different reactions. Four FL 
plasmids containing the N gene in the M-F intergenic region were found positive 
both to PCR and RE screening and four plasmids were positive for the M gene 
insertion.  
The S1 gene was added by site directed mutagenesis (SDM) at the G-L intergenic 
region of plasmid cBN M-F, as demonstrated by the gene being detected in three 
clones by PCR and RE screening.  
The cloning cassette was added by SDM at the G-L junction of cBN M-F and M gene 
amplicons ligated into it. Eight clones containing the M gene at G-L junction and 
the one clone containing the N gene at M-F were detected by PCR and RE screening.  
Sequencing analyses confirmed that no mutations were present in the exogenous 
genes of any clones. 
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7.3.2 Recovery of recombinant viruses 
Several rescue attempts were performed for each constructs, but none generated 
virus.  
 
7.3.2.1 cBN M-F rescue attempts 
Vero cells monolayers transfected with construct cBN M-F were viewed daily for the 
presence of cytopathic effect (CPE). After 6 days post infection (d.p.i.) on the 
second passage no CPE was detected. After 25 d.p.i. cellular changes were 
observed; but not clear CPE. After 31 d.p.i. areas similar to CPE was observed. A 
further passage was performed, but no CPE was detected. Potential avian 
metapneumovirus (AMPV) RNA was extracted from the cell monolayer but viral 
mRNA wasn’t detected.   
 
7.3.2.2 cBN M-F S1+IL-18 G-L and cBM M-F S1+IL-18 G-L rescue attempts 
Constructs cBN M-F S1+IL-18 G-L and cBM M-F S1+IL-18 G-L were transfected into Vero cells. 
After 28 d.p.i. some areas of the second passage showed cellular changes. After 49 
d.p.i. clear CPE was not detected and a third passage was performed. After 24 d.p.i 
on the third passage the Vero cell monolayers didn’t show any signs of CPE. RT-
PCR didn’t detect any AMPV mRNA. 
 
7.3.2.3 cBN M-F S1 G-L rescue attempts 
The construct was transfected into Vero cell monolayers and viewed daily for CPE. 
After 30 d.p.i, the second passage contained a few areas of cellular change. A third 
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passage was performed, but after 24 d.p.i no sign of CPE was detected. RT-PCR 
against AMPV viral mRNA was negative. 
 
 
7.3.2.4 cBN M-F N G-L rescue attempts 
The construct was transfected on Vero cell monolayers and viewed daily for CPE. 
At 23 d.p.i., the second passage contained some areas cellular changes. After 48 
d.p.i. a third passage was performed, but after 24 d.p.i. no sign of CPE was seen. 
RT-PCR direct against AMPV didn’t detect viral mRNA. 
 
 
 
Clone name Insert gene Position No. Plasmids Rescued/attempts 
cBN M-F N M-F  1 0/1 
cBN M-F+S1 G-L N and S1 M-F and G-L 3 0/3 
cBN M-F+S1+IL-18 
G-L 
N, S1 and IL-18 M-F and G-L 4 0/ 
cBM M-FS1+IL-18 G-
L 
M, S1 and IL-
18 
M-F and G-L 4 0/4 
cBN M-F+M G-L N and M M-F and G-L 8 0/8 
Table 7.2 Summary of the constructed recombinant cloned FL cDNAs 
 
 
7.4 DISCUSSION 
 
In the present study several rational attempts to increase the ability of subtype B 
recombinants to induce protective immunity were performed as based on the data 
obtained from previous chapters and from a study of subtype A recombinants 
(Falchieri et al., 2013). Several constructs were obtained, containing up to three 
exogenous genes in two different intergenic regions, but none of them was rescued, 
despite several attempts and longer passages on Vero cells.  
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The plasmids transfected into Vero cells were all based on the hybrid genome copy 
generated in a previous study, but they differ in the number of exogenous genes 
inserted. The common feature between all the plasmids was the presence of an 
exogenous gene in the M-F intergenic region, strongly suggesting that the insertion 
of a foreign gene at that particular intergenic region compromised the virus viability 
of subtype B recombinants. These data contrast with what has been observed for 
subtype A, where the M-F junction represented the best compromised between 
exogenous gene expression and virus viability (Falchieri et al., 2013). A different 
behaviour between the two subtypes is the most likely explanation for the 
conflicting results obtained in the two studies, but also other conclusions might be 
drawn. In their study, Falchieri et al. (2013) cloned QX N or QX S1 genes at the M-
F junction, while in the present study Massachusetts (Mass) N or Mass M genes 
have been cloned. It is unlikely that the different strains or the different genes used 
in our study caused the lack of virus viability, but at the moment this hypothesis 
cannot be fully put aside. In the previous chapter we have observed that the rescue 
of a plasmid containing the IL-18 gene and an IBV gene in the same intergenic 
region, can only be achieved when the IBV gene was the S1 and not the N, 
suggesting that a particular sequence or a particular combination of sequences can 
prevent the recovery of the virus. These could be easily verified inserting QX S1 or 
QX N gene in the M-F intergenic region of the hybrid subtype B plasmid and 
subsequently attempting the virus rescue. Nevertheless a more rational approach 
could be adopted to verify these two hypothesises and to obtain at the same time 
useful information for further studies. The construction of seven subtype B hybrid 
plasmids containing a reporter gene in a different intergenic region would determine 
the viability of each virus and of the exogenous gene expression with respect to 
every intergenic region. 
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As previously mentioned, the failure to recover virus containing the M gene makes 
it impossible to currently evaluate the ability of the M protein to stimulate a 
protective immune response. To most conveniently address this, it   should be 
possible to insert the M gene at the G-L junction of the hybrid AMPV genome copy 
and testing this in homologous IBV challenge studies.   
The flexibility of making different constructs confirmed the suitability of AMPV 
subtype B as a vector for the development of recombinant vaccines. Up to 4000 
exogenous nucleotides have been inserted in two different intergenic regions of 
subtype B genome. Nevertheless, the insertion of an exogenous gene at the M-F 
junction seems to have compromised the virus viability causing failure in the 
recovery of the recombinants. Future studies should focus on subtype B 
recombinant viability, as such studies would allow us to determine the intergenic 
regions showing the best balance between virus viability and exogenous genes 
expression. That knowledge could be crucial in the development of effective 
subtype B recombinant vaccines. 
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8. CONCLUSION 
Reverse genetics (RG) was first applied to avian metapneumovirus subtype A and 
C (Govindarajan et a., 2006; Naylor et al., 2004), and different studies investigated 
the effects of single and multiple genomic mutations (Brown et al., 2011; Naylor et 
al., 2006; Naylor et al., 2013) gene deletions (Ling et al., 2008; Yu et al., 2011) and 
insertions (Govindarajan et al., 2006; Lupini et al., 2008) on virus phenotype. To 
extend this to subtype B, several attempts had been previously made to establish a 
subtype RG system but these failed. In the current study, a RG system for subtype 
B was developed for the first time (chapter 4), then used to investigate subtype B as 
a vector for the expression of infectious bronchitis virus (IBV) genes (chapter 5). 
Attempts to confer the protection induced by the recombinants against IBV was 
described in chapters 6 and 7.  
In chapter 4 a comparison was made of the AMPV subtypes A and B amino acids 
sequences. The analysis focused initially on the genes forming the Ribonuclear 
Complex (RNP), directly involved in the RG system (Naylor et al., 2004) and 
showed there to be high identities and similarities between the two subtypes. When 
compared to subtype C, less identity and similarity were observed. The analysis was 
extended to the leader and trailer nucleotide sequences, and to the gene transcription 
start and stop sequences. The first 12 bases of the leader of all the three subtypes 
and of subtype A trailer were identical, while 2 mismatches were observed in 
subtype B and C. A common antigenome sequence was also found in the trailer of 
all the subtypes, between nucleotide 13-21. More studies need to be done to 
understand the role of these sequence. A common transcription start sequence was 
observed in the three subtypes, with the exception of the L gene, and of the G and 
SH genes in subtype B. The analysis of the transcription stop detected some slight 
differences between subtypes: nevertheless, the differences observed were no 
greater than those identified within subtypes. The data indicated that subtypes A 
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and B might be recovered using support genes of both the subtypes. Plasmids 
containing the B type support genes, as well as plasmids containing the full genome 
copy of a subtype B virus were obtained. Virus was rescued from subtypes A or B 
full length genome copies using either A or B support plasmids. These data 
confirmed that the polymerase of either subtype can recognise leader, trailer and 
gene start and stop sequences. For the first time a subtype B virus was recovered. 
The differences detected in subtype C when compared to subtypes A and B are 
greater to those found between subtypes A and B, hence it is not clear if a common 
RG system might be possible. 
Chapter 5 described the construction of two subtype B recombinant viruses, 
carrying the S1 and the N genes of IBV. The S1 and N proteins had previously 
proved able to induce protective immunity (Cavanagh. 2007; Seo et al., 1999; Yu 
et al., 2001). The genes were inserted into the intergenic region between the G and 
L genes of AMPV and recombinant viruses were successfully rescued. AMPV 
subtype B proved able to replicate and transcribe the exogenous genes in vitro. In 
vivo the recombinants gave poor protection, assessed by observing tracheal cilial 
motility after virulent challenge with IBV. Recombinant replication in the 
respiratory tract was poor, and a serological responses against AMPV were largely 
absent. The poor replication in the trachea was associated with negligible protection. 
To increase replication and possibly protection, the genes involved in attachment 
and release of the virus from the host cell were modified and a chimera full length 
AMPV subtype B sequence was obtained (see chapter 6). S1 and N sequences were 
cloned into the chimera subtype B and chimera recombinant viruses were rescued. 
The replication in the trachea was very high and the protection induced by subtypes 
B chimera recombinant was generally improved in comparison to subtypes A 
(Falchieri et al., 2013) and previous subtype B recombinants (chapter 5). A better 
protection was observed in birds vaccinated with recombinant AMPV expressing 
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the N gene, suggesting that this protein is the major immunogenic protein of IBV. 
Nevertheless the pharmacopeia efficacy requirement was not met. It remains 
unclear whether the failure to confer full protection might be attributed to the low 
exogenous gene expression or perhaps the lack of expression of as yet unrecognised 
immunogenic IBV proteins.  
In chapter 6 interleukin 18 (IL-18) was added in the chimera plasmids downstream 
the IBV gene, as IL-18 stimulates the release of interferon ɣ (IFN-ɣ) (Schneider et 
al., 2000) and has been shown to enhance vaccine efficacy (Göbel et al., 2003; 
Winfried et al., 2004). Only virus containing both the S1 and the IL-18 genes was 
rescued. Chickens inoculated with this recombinant were challenged in vivo, and 
found to be better protected than recombinants expressing only the S1. Surprisingly 
it was not possible to rescue virus expressing N and Il-18 proteins. It’s likely that 
the presence of these two foreign genes in the same intergenic region removed virus 
viability. 
In chapter 7 further attempts to increase the protection conferred by the 
recombinants were described. The N gene was inserted at the M-F junction to 
increase the protein expression without affecting virus viability, as suggest by a 
study carried on subtype A recombinants (Falchieri et al., 2013). That same study 
indicated that the coexpression of more than one IBV genes conferred better 
protection (Falchieri et al., 2013). Several plasmids containing two IBV genes were 
obtained. None of plasmids generated successfully produced virus. The presence of 
an exogenous gene at the M-F junction might have compromised the virus viability. 
Further studies need to be done to fully understand the subtype B viability in respect 
to the site of insertion of the exogenous genes.  
In conclusion, the first AMPV subtype B RG has been developed. It has been shown 
that subtypes B and A support protein genes can rescue both subtype B or A full 
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length genome copies. AMPV subtype B proved tolerant in accepting extra genes 
at intergenic positions and several recombinants viruses were successfully rescued. 
Inserted nucleotide sequences were conserved during passage in vitro, and 
transcription and expression of foreign genes were demonstrated. Nevertheless the 
viral viability appeared to be affected depending on the site of insertions. 
Furthermore, the size limit of inserted exogenous nucleotides is still not determined. 
The recombinant viruses have been tested as candidate vaccines in chickens against 
IBV and despite some promising results, more studies needs to be done in order to 
develop efficacious AMPV-B/IBV recombinant vaccines.  
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